Medical genetics Books

Book SynopsisOut of the study of the intricacies of the genome and gene regulation, arose a new science that was independent of actual DNA changes, but critical in maintaining gene regulation and genetic stability.Trade ReviewFrom the reviews:“The book by Kovalchuk and Zemp is a successful attempt to provide the most recent approaches for identifying epigenetic variation in plants. … it is without doubts that the publication should be in every bookcase of molecular scientists interested in epigenetics. I can also recommend it for plant ecologists and evolutionists engaged in epigenetic variation in plants because some methods can be a good improvement of the currently commonly used approaches.” (Vit Latzel, Folia Geobotanica, Vol. 48, 2013)Table of ContentsTable of Contents Preface Contributors Analysis of DNA Methylation in Plants by Bisulfite Sequencing Andrea M. Foerster and Ortrun Mittelsten Scheid Analysis of bisulfite sequencing data from plant DNA with CyMATE Andrea M. Foerster, Jennifer Hetzl, Christoph Müllner and Ortrun Mittelsten Scheid Analysis of locus-specific changes in methylation patterns using a COBRA (combined bisulfite restriction analysis) assay Alex Boyko and Igor Kovalchuk Detection of changes in global genome methylation using the cytosine-extension assay Alex Boyko and Igor Kovalchuk In situ analysis of DNA methylation in plants Palak Kathiria and Igor Kovalchuk Analysis of mutation/rearrangement frequencies and methylation patterns at a given DNA locus using RFLP (restriction fragment length polymorphism) Alex Boyko and Igor Kovalchuk Isoschizomers and Amplified Fragment Length Polymorphism (AFLP) for the Detection of Specific Cytosine Methylation Changes Leonor Ruiz-García, Jose Antonio Cabezas, Nuria de María, María-Teresa Cervera Analysis of small RNA populations using hybridization to DNA tiling arrays Martine Boccara, Alexis Sarazin, Bernard Billoud, Agnes Bulski, Louise Chapell, David Baulcombe and Vincent Colot Northern blotting techniques for small RNAs Todd Blevins qRT-PCR of small RNAs Erika Varkonyi-Gasic and Roger P. Hellens Cloning new small RNA sequences Yuko Tagami, Naoko Inaba and Yuichiro Watanabe Genome-wide Mapping of Protein-DNA Interaction by Chromatin Immunoprecipitation and DNAMicroarray Hybridization (ChIP-chip). Part A – ChIP-chip Molecular Methods Julia J. Reimer and Franziska Turck Genome-wide mapping of protein-DNA interaction by chromatin immunoprecipitation and DNA microarray hybridization (ChIP-chip). Part B – ChIP-chip data analysis Ulrike Göbel and Franziska Turck Metaanalysis of ChIP-chip data Julia Engelhorn and Franziska Turck Chromatin Immunoprecipitation Protocol for Histone Modifications and Protein-DNA Binding Analyses in Arabidopsis Stéphane Pien, Ueli Grossniklaus cDNA Libraries for Virus-Induced Gene Silencing Andrea T. Todd, Enwu Liu and Jonathan E. Page Detection and quantification of DNA strand breaks using the ROPS (random oligonucleotide primed synthesis) assay Alex Boyko and Igor Kovalchuk Reporter gene-based recombination lines for studies of genome stability Palak Kathiria and Igor Kovalchuk Plant transgenesis Alicja Ziemienowicz

Read more less

Book SynopsisLong regarded as biological waste, the placenta is gaining momentum as a viable product for clinical use. Due to their unique properties, placental cells and derivatives show great promise in curing various diseases. Utilizing contributions from world-renowned experts, Placenta: The Tree of Life considers the therapeutic potential of these cells. It examines new stem cellbased strategies and highlights recent studies that advance the range of treatment for a number of illnesses. Emphasizing the potential research and therapeutic use of stem cells, the book discusses the development, structure, and functions of the human placenta. It introduces overall aspects of the immune system, explains some of the immune mechanisms during pregnancy, and shows the role of the placenta in these mechanisms. Current scientific research is presented that focuses on the mechanisms of action underlying the therapeutic benefit of cells isolated from different placental regionTable of ContentsStructure and Development of the Human Placenta. The Role of Mesenchymal Stem Cells in the Functions and Pathologies of the Human Placenta. The Roles of the Human Placenta in Fetal-Maternal Tolerance. The Human Placenta in Wound Healing: Historical and Current Approaches. Cell Populations Isolated from Amnion, Chorion, and Wharton’s Jelly of Human Placenta. The Immunomodulatory Features of Mesenchymal Stromal Cells Derived from Wharton’s Jelly, Amniotic Membrane, and Chorionic Villi: In Vitro and In Vivo Data. Use of Placenta-Derived Cells in Neurological Disorders. Use of Amnion Epithelial Cells in Metabolic Liver Disorders. The Use of Placenta-Derived Cells in Autoimmune Disorders. The Use of Placenta-Derived Cells in Inflammatory and Fibrotic Disorders. From Bench to Bedside: Strategy, Regulations, and Good Manufacturing Practice Procedures. Applications of Placenta-Derived Cells in Veterinary Medicine.

Read more less

Book SynopsisAdenoviruses are double stranded DNA viruses that have been used to study the process of DNA replication. Studies of the mode of action of adenovirally produced tumors in rodents led to the discovery of tumour supressor genes. The adenoviral vector is now the most used vector in clinical gene therapy especially for some kinds of cancers. The chapters in this book focus on the most up-to-date developments in the therapeutic applications of adenoviruses. The intended audience is individuals in the Life Sciences interested in therapeutic applications of adenoviruses. This book reviews the life history and immune responses to adenoviruses and summarizes various therapies implemented with the use of adenoviruses.Table of ContentsAdenovirus Biology: Virus structure and life cycle. Immune responses to adenovirus. Helper-dependent adenoviral vectors for gene and cell therapy. Genetic and capsid modified Adenovirus. Adenovirus for vaccination. FGAd and HDAd. Adenovirus vectors for cancer therapy. Adenovirus-based hybrid vectors. FDA expectations and requirements of adenoviral products.

Read more less

Book Synopsis

Read more less

Book SynopsisGute Daten + gute Statistik = gute Ergebnisse! Mit diesem Buch haben falsche Statistiken keine Chance mehr. Übersichtlich gegliedert in 6 Teile mit zusammen 20 Kapiteln werden hier alle wichtigen Typen von Daten und die Verfahren zu deren Auswertung erklärt. Die erklärte Maxime des Autors ist es, dass sich eine statistische Auswertung immer an der Art und Qualität der Daten orientieren muss, damit diese nicht fehl- oder überinterpretiert werden. Komplizierte Mathematik ist dabei weder nötig noch erwünscht, denn meistens sind die einfachsten Verfahren die aussagekräftigsten. Ein positiver Lerneffekt stellt sich bereits nach wenigen Seiten ein, denn hier werden genau die Fragen gestellt (und beantwortet!), mit denen ein angehender Mediziner oder Pharmazeut während der Ausbildung konfrontiert wird. Mit seinem ungezwungenen und direkten Stil gelingt es dem Autor, dass die Statistik vom ungeliebten Kind zum effizienten Werkzeug wird, auch ohne mathematische Begabung beim Leser. * Leicht verständliche Texte (fast) ohne Formeln * Alle Beispiele kommen aus der Medizin oder der Pharmazie * Warnhinweise auf häufi ge Fehler und auf den unsachgemäßen Einsatz von Statistiken Als leicht verständliche Einführung in die statistischen Grundlagen und Verfahren, die in der Medizin und in der Pharmazie eingesetzt werden, ist dieses Buch bestens geeignet für alle, die eine Ausbildung im medizinischpharmazeutischen Bereich absolvieren.Trade Review"Rowes rundum gelungenes Grundlagenwerk ist das mit Abstand beste Statistikbuch für naturwissenschaftliche Anfänger, das mir bislang untergekommen ist. Es balanciert präzise auf jenem schmalen Grat zwischen (zu)komplizierter Mathematik und oberflächlichem Blabla. Folgerichtiger Ratschlag: Kaufen!" Laborjournal (01.12.2016) "Eines der wenigen verständlich geschriebenen Bücher, das auch gering vorgebildete Studenten nicht abschreckt, sondern als Einstieg in die Statistik genutzt werden kann. Didaktisch ist das Buch sehr gut gelungen. Man bemerkt kaum, dass es sich um eine Übersetzung handelt. Das Preis-Leistungsverhältnis ist sehr gut. Das Buch wird sicher nicht nur als Prüfungsvorbereitung genutzt werden, sondern erleichtert auch Doktoranden und Jungwissenschaftlern den Umgang mit der immer komplizierter werdenden Statistik." Prof. Dr. Dr. Harald Kaemmerer, Klinik an der TU München (01/2013) "übersichtlich, lehrreich und einprägsam" uni-online.de (05.02.2013) "sehr schön und übersichtlich aufgebaut" uni-online.de (07.01.2013) "ein didaktisch sehr gut aufgearbeitetes und verständliches Lehrbuch" uni-online.de (03.12.2012) "Dieses Buch hat [...] mit Recht den Aufdruck 'Verdammt clever' verdient." uni-online.de (20.11.2012) "Mit unnachahmlichem Stil, durch den auch dieses Fachgebiet seinen Schrecken verliert, präsentiert der Autor das Lehrbuch." PharmaTEC (8/2012, 01.11.2012) "Rowe versteht es, auch für Leser ohne ausgeprägte mathematische Begabung Torten-, Balken- und Kurvendiagramme mit Leben zu erfüllen." apotheke + marketing (11/2012, 01.11.2012) "Ja, Statistik kann auch Spaß machen! Philip Rowe ist bekannt für seinen unnachahmlichen Stil, durch den dieses Fachgebiet für Statistikmuffel an Schrecken verliert." Deutsche Apotheker Zeitung (Nr. 37, 13.09.2012) "Eine verständliche Einführung in die statistischen Grundlagen und Verfahren, die in der Medizin und in der Pharmazie angewandt werden." medknowledge.de (10.09.2012)Table of ContentsVORWORT TEIL1: Datentypen DATENTYPEN Kommt es wirklich darauf an? Daten auf einer Intervallskala Daten auf einer Ordinalskala Daten auf einer Nominalskala Aufbau dieses Buchs Kapitelzusammenfassung TEIL2: Daten auf Intervallskalen BESCHREIBENDE STATISTIK Zusammenfassung von Datensätzen Zentrale Lagemaße - der Mittelwert, der Median und der Modalwert Beschreibung der Spannweite - die Standardabweichung und die relative Standardabweichung Quartile - eine andere Möglichkeit, Daten zu beschreiben Verwendung von Software für die beschreibende Statistik Kapitelzusammenfassung DIE NORMALVERTEILUNG Was ist eine Normalverteilung? Wie erkennt man normalverteilte Daten? Anteile von Einzelwerten innerhalb von einer oder zwei Standardabweichungen vom Mittelwert Kapitelzusammenfassung STICHPROBEN AUS EINER GRUNDGESAMTHEIT UND DER STANDARDFEHLER DES MITTELWERTS Stichproben und Grundgesamtheiten Von der Stichprobe zur Grundgesamtheit Verschiedene Stichprobenfehler Welche Faktoren bestimmen die Höhe des zufälligen Stichprobenfehlers? Abschätzung des wahrscheinlichen Stichprobenfehlers und der Standardfehler Aufrechnung von Stichprobengröße und Standardabweichung Kapitelzusammenfassung DAS 95 %-KONFIDENZINTERVALL FÜR DEN MITTELWERT Was ist ein Konfidenzintervall? Wie breit sollte das Intervall sein? Was meinen wir mit ''95 %''-Konfidenz? Berechnung der Intervallbreite Eine Reihe von Stichproben und 95 %-Konfidenzintervallen Wie stark hängt die Breite des Konfidenzintervalls von Änderungen der Standardabweichung, des Stichprobenumfangs und des gewünschten Konfidenzniveaus ab? Zwei Aussagen Einseitige 95 %-Konfidenzintervalle Das 95 %-Konfidenzintervall für den Unterschied zweier Behandlungen Über die Notwendigkeit, dass die Daten einer Normalverteilung folgen und Datentransformation Kapitelzusammenfassung DER DOPPELTE T-TEST (1). EINFÜHRUNG IN HYPOTHESENTESTS Der doppelte t-Test - ein Beispiel für einen Hypothesentest Signifikanz Das Risiko eines falsch-positiven Ergebnisses Von welchen Faktoren hängt es ab, ob wir ein signifikantes oder ein nicht signifikantes Ergebnis erhalten? Voraussetzungen für einen doppelten t-Test Kapitelzusammenfassung DER DOPPELTE T-TEST (2): DER BERÜCHTIGTE P-WERT Wie kann man die Signifikanz eines Ergebnisses beziffern? p-Werte Gibt es zwei Arten, Signifikanz zu definieren? Bestimmung des p-Wertes p-Werte oder 95 %-Konfidenzintervalle? Kapitelzusammenfassung DER DOPPELTE T-TEST (3). FALSCH-NEGATIVE BEFUNDE, GÜTE UND NOTWENDIGE STICHPROBENUMFÄNGE Was könnte sonst noch schief gehen? Die Güte Berechnung des notwendigen Stichprobenumfangs Kapitelzusammenfassung DER DOPPELTE T-TEST (4). STATISTISCHE SIGNIFIKANZ, PRAKTISCHE BEDEUTUNG UND ÄQUIVALENZ Praktische Bedeutung - ist die Differenz so groß, dass sie eine Rolle spielt? Äquivalenztests Tests auf Nicht-Unterlegenheit p-Werte sind weniger aussagekräftig und können förmlich in die Irre führen Setzen von Äquivalenzgrenzen vor dem eigentlichen Versuch Kapitelzusammenfassung DER DOPPELTE T-TEST (5). EINSEITIGE TESTS Suche nach einer Veränderung in einer bestimmten Richtung Schutz vor falsch-positiven Befunden Versuchung Einsatz eines Softwarepakets bei einem einseitigen Test Sollte man häufiger einseitige Tests einsetzen? Kapitelzusammenfassung WAS SAGT UNS EIN STATISTISCH SIGNIFIKANTES ERGEBNIS WIRKLICH? Wie interpretiert man statistische Signifikanz? Am Anfang steht äußerste Skepsis Kapitelzusammenfassung DER GEPAARTE T-TEST - VERGLEICH VON ZWEI ZUSAMMENHÄNGENDEN DATENSÄTZEN Gepaarte Datensätze Untersuchung der Daten mithilfe eines doppelten t-Tests Alternative Anwendung eines gepaarten t-Tests Durchführung eines gepaarten t-Tests Wodurch ist bestimmt, ob ein gepaarter t-Test signifikant ist? Größere Teststärke beim gepaarten t-Test Der gepaarte t-Test ist nur auf natürliche Paare von Daten anwendbar Auswahl des passenden Versuchsaufbaus Voraussetzungen für das Anwenden eines gepaarten t-Tests Stichprobenumfänge, praktische Bedeutung und einseitige Tests Zusammenfassung der Unterschiede zwischen dem gepaarten und dem doppelten t-Test VARIANZANALYSE - ÜBER T-TESTS HINAUS Erweiterung zu komplexen Versuchsdesigns Einfache Varianzanalyse Zweifache Varianzanalyse Multifaktorenversuche Einfache Form - starke Aussage Kapitelzusammenfassung KORRELATION UND REGRESSION - ZUSAMMENHÄNGE ZWISCHEN MESSWERTEN Korrelationsanalyse Regressionsanalyse Mehrfache Regression Kapitelzusammenfassung TEIL3: Daten auf Nominalskalen BESCHREIBUNG VON KATEGORISIERTEN DATEN Beschreibende Statistik Tests, ob der wahre Anteil möglicherweise einen vorbestimmten Wert hat Kapitelzusammenfassung VERGLEICH BEOBACHTETER ANTEILE - DER CHI-QUADRAT-KONTINGENZTEST Anwendung des Chi-Quadrat-Kontingenztests für den Vergleich von beobachteten Anteilen Ein 95 %-Konfidenzintervall für die Änderung der Ausstoßquote - ist die Änderung von praktischer Bedeutung? Größere Kontingenztafeln - Nutzung der Diabetes-Sprechstunde Planung der Versuchsgröße Kapitelzusammenfassung TEIL4: Daten auf Ordinalskalen ORDINALSKALIERTE, NICHT NORMALVERTEILTE DATEN. TRANSFORMATIONEN UND PARAMETERFREIE TESTS Transformation auf eine Normalverteilung Der Mann-Whitney-Test - ein nicht parametrisches Verfahren Umgang mit Daten auf Ordinalskalen Andere nicht parametrische Verfahren Kapitelzusammenfassung Anhang zu Kapitel 17 TEIL5: Reale Herausforderungen MEHRFACHTESTS Was ist ein Mehrfachtest und warum ist er problematisch? Wo treten Mehrfachtests auf? Verfahren zur Vermeidung von Falsch-positiven Die Rolle der wissenschaftlichen Zeitschriften Kapitelzusammenfassung FRAGEBÖGEN Gibt es Besonderheiten bei Fragebögen? Arten von Fragen Entwurf eines Fragebogens Stichprobenumfang und Rücklaufquoten Untersuchung der Ergebnisse Verquickte epidemiologische Daten Mehrfachtests bei Fragebogendaten Kapitelzusammenfassung TEIL6: Fazit SCHLUSSFOLGERUNGEN Machen Sie sich das Ziel des Versuchs klar Bauen Sie den Versuch einfach und damit klar und aussagekräftig auf Planen Sie die statistischen Analysen schon als Teil des Versuchsdesigns und nicht erst auf den letzten Drücker Untersuchen Sie die Daten visuell, bevor Sie in die statistischen Tests einsteigen Hüten Sie sich vor Mehrfachtests Interpretieren Sie sowohl Signifikanz als auch Nicht-Signifikanz mit gebührender Sorgfalt

Read more less

Table of Contents1 Wachstum naturwissenschaftlicher Erkenntnis: Einführung in die Wissenschaftstheorie von Thomas Kuhn.- 1.1 Paradigma, Anomalie, Krise und Revolution: Die Begriffe bei Thomas Kuhn.- 1.2 Kuhns Paradigma-Begriff aus der Sicht der Gestalttheorie.- 1.3 Bedeutung von Musterbeispielen in der Welterfahrung des heranwachsenden Kindes.- 1.4 Erster Exkurs: Unmögliche Gestalten.- 2 Wachstum naturwissenschaftlicher Erkenntnis: Von der Zelltheorie bis zur Chromosomentheorie der Vererbung.- 2.1 Zur Entwicklungsgeschichte der Mikroskopie und Histologie.- 2.2 Vorläufer der Zelltheorie: Franz Julius Ferdinand Meyen.- 2.3 Die Zelltheorie bei Schleiden und Schwann.- 2.4 Wissenschaftstheorie bei Schwann und Schleiden.- 2.5 Krise der Zelltheorie: Wie bilden sich Zellen?.- 2.6 Zellkern und Befruchtungslehre.- 2.7 Die Entdeckung der Chromosomen.- 2.8 Zweiter Exkurs: Zur Rolle von Wissenschaftssprache und esoterischen Objekten beim Wachstum wissenschaftlicher Erkenntnis.- 2.9 Kontinuität oder Auflösung der Chromosomen in der Interphase? Das Paradigma der Chromosomenindividualität.- 2.10 Chromosomentheorie der Vererbung vor 1900: August Weismanns Versuch einer „realen“ Theorie.- 2.11 Die Geburt der Genetik: Das Paradigma von Gregor Mendel.- 2.12 Chromosomentheorie der Vererbung nach 1900: Walter S. Sutton und Theodor Boveri.- 2.13 Cytogenetik in der Lyssenko-Ära: Ein illegitimer Paradigmawechsel.- 3 Betrachtungen zum Wachstum wissenschaftlicher Erkenntnis.- 3.1 Kuhns Theorie des Paradigmawechsels und die Geschichte der frühen Zell- und Verer-bungsforschung: Ein kritischer Vergleich.- 3.2 Wie wächst wissenschaftliche Erkenntnis?.- a) Was bedeutet „Wachstum“ im Erkenntnisprozeß?.- b) Gibt es Regeln für den Entwurf naturwissenschaftlicher Paradigmata? Anmerkungen zur Rolle von Theorie und Beobachtung.- 3.3 Der Wunsch nach geschlossenen Theorien und die Unvermeidbarkeit von Krisen im Wachstum der Erkenntnis. Bemerkungen aus dem Blickwinkel einer evolutionären Erkenntnistheorie.- 3.4 Sehen und räumliches Vorstellungsvermögen aus dem Blickwinkel einer evolutionären Erkenntnistheorie: der Mesokosmos als ,kognitive Nische‘ des Menschen.- Dritter Exkurs: Eschers Belvedere und das Raumproblem.- Vierter Exkurs: Naive und naturwissenschaftliche Raumerfahrung in einem zweidimensionalen Mesokosmos.- 3.5 Schlußbetrachtung: Entwicklung der Chromosomentheorie und Menschenbild.- 4 Anmerkungen.- 5 Postscriptum — Ludwik Fleck (1896–1961) der Vorläufer von Thomas Kuhn: Die Theorie vom Denkstil und den Denkstilumwandlungen in wissenschaftlichen Gemeinschaften.- 6 Literatur.- 7 Namenverzeichnis.- 8 Sachverzeichnis.

Read more less

Book SynopsisAdvocates a conversation around the genetic risk for breast and ovarian cancers that focuses less on choice and more on care. Offers a new set of conceptual starting points for understanding what is at stake with a BRCA diagnosis and what the focus on choice obstructs from view. Trade Review“This book is groundbreaking, not only for scholars interested in women’s health, or health or science studies more generally, but also for rhetorical scholars and (post)humanists.”—Celeste M. Condit,author of Angry Public Rhetorics: Global Relations and Emotion in the Wake of 9/11“Being at Genetic Risk delves deeply into Mol’s concept of ‘logic of care’; set in the context of the risk of a genetic disease (rather than focusing on patients living with a disease or a difficult-to-define symptom), this adds in significant and interesting ways to the conversation.”—Jodie Nicotra,University of Idaho“Kelly Pender’s Being at Genetic Risk: Toward a Rhetoric of Care makes an important contribution to scholarship in the rhetoric of health and medicine (RHM); rhetoric of science, technology, and medicine (RSTM); and rhetoric more broadly. The book does so by taking on the important task of questioning critiques ‘debunking’ social creations that dupe naïve people into believing their reality.”—Cathryn Molloy Rhetoric Review

Read more less

Book SynopsisOne of the world’s leading cultural psychologists debunks the hype surrounding DNA testing and puts to rest our mistaken anxieties about our genes.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis fourth edition of the best-selling textbook, Human Genetics and Genomics, clearly explains the key principles needed by medical and health sciences students, from the basis of molecular genetics, to clinical applications used in the treatment of both rare and common conditions.Table of ContentsPreface vii How to get the best out of your textbook viii PART ONE: BASIC PRINCIPLES OF HUMAN GENETICS 1 1 DNA Structure and Function 3 2 Genetic Variation 20 3 Patterns of Inheritance 38 4 The Human Genome 64 5 Multifactorial Inheritance 87 6 Cell Division and Chromosomes 100 7 Population Genetics 125 8 Cancer Genetics 137 PART TWO: GENETICS AND GENOMICS IN MEDICAL PRACTICE 155 9 Chromosome Translocation 157 10 Molecular Diagnosis 171 11 Newborn Screening 182 12 Developmental Genetics 194 13 Carrier Screening 203 14 Genetic Risk Assessment 213 15 Genetic Testing for Risk of Cancer 222 16 Pharmacogenetics 230 17 Treatment of Genetic Disorders 239 Answers to Review Questions 248 Glossary 253 Index 262

Read more less

Book SynopsisHuman Drug Metabolism, An Introduction, Second Edition provides an accessible introduction to the subject and will be particularly invaluable to those who already have some understanding of the life sciences. Completely revised and updated throughout, the new edition focuses only on essential chemical detail and includes patient case histories to illustrate the clinical consequences of changes in drug metabolism and its impact on patient welfare. After underlining the relationship between efficacy, toxicity and drug concentration, the book then considers how metabolizing systems operate and how they impact upon drug concentration, both under drug pressure and during inhibition. Factors affecting drug metabolism, such as genetic polymorphisms, age and diet are discussed and how metabolism can lead to toxicity is explained. The book concludes with the role of drug metabolism in the commercial development of therapeutic agents as well as the pharmacology of some illicit drugs.<Trade ReviewReviews of first edition: "The author has certainly achieved his goal of providing an accessible introduction to human drug metabolism" (The Annals of Pharmacotherapy, June 2006) "Armed with the knowledge contained in this book, we should all be well on the way" (Pharmaceutical Physician, May 2006) "…a useful introductory text for the intended audience of students studying pharmacology and toxicology…" (Veterinary Pathology, November 2006)Table of ContentsPreface. Preface to First Edition. 1. Introduction. 1.1 Therapeutic window. 1.2 Consequences of drug concentration changes. 1.3 Clearance. 1.4 Hepatic extraction and intrinsic clearance. 1.5 First pass and plasma drug levels. 1.6 Drug and xenobiotic metabolism. 2. Drug Biotransformational Systems – Origins and Aims. 2.1 Biotransforming enzymes. 2.2 Threat of lipophilic hydrocarbons. 2.3 Cell communication. 2.4 Potential food toxins. 2.5 Sites of biotransforming enzymes. 2.6 Biotransformation and xenobiotic cell entry. 3. How Oxidative Systems Metabolize Substrates. 3.1 Introduction. 3.2 Capture of lipophilic molecules. 3.3 Cytochrome P450s classification and basic structure. 3.4 CYPs – main and associated structures. 3.5 Human CYP families and their regulation. 3.6 Main human CYP families. 3.7 Cytochrome P450 catalytic cycle. 3.8 Flavin monooxygenases (FMOs). 3.9 How CYP isoforms operate in vivo. 3.10 Aromatic ring hydroxylation. 3.11 Alkyl oxidations. 3.12 ‘Rearrangement’ reactions. 3.13 Other oxidation processes. 3.14 Control of CYP metabolic function. 4. Induction of Cytochrome P450 Systems. 4.1 Introduction. 4.2 Causes of accelerated clearance. 4.3 Enzyme induction. 4.4 Mechanisms of enzyme induction. 4.5 Induction – general clinical aspects. 5. Cytochome P450 Inhibition. 5.1 Introduction. 5.2 Inhibition of metabolism – general aspects. 5.3 Mechanisms of inhibition. 5.4 Cell transport systems and inhibition. 5.5 Major clinical consequences of inhibition of drug clearance. 5.6 Use of inhibitors for positive clinical intervention. 5.7 Summary. 6. Conjugation and Transport Processes. 6.1 Introduction. 6.2 Glucuronidation. 6.3 Sulphonation. 6.4 The GSH system. 6.5 Glutahione S-transferases. 6.6 Epoxide hydrolases. 6.7 Acetylation. 6.8 Methylation. 6.9 Esterases/amidases. 6.10 Amino acid conjugation (glycine or glutamate). 6.11 Phase III transport processes. 6.12 Biotransformation-integration of processes. 7. Factors Affecting Drug Metabolism. 7.1 Introduction. 7.2 Genetic polymorphisms. 7.3 Effects of age on drug metabolism. 7.4 Effects of diet on drug metabolism. 7.5 Gender effects. 7.6 Smoking. 7.7 Effects of ethanol on drug metabolism. 7.8 Artificial livers. 7.9 Effects of diseases on drug metabolism. 9.10 Summary. 8. Role of Metabolism in Drug Toxicity. 8.1 Adverse drug reactions: definitions. 8.2 Reversible drug adverse effects: Type A. 8.3 Irreversible drug toxicity: Type B. 8.4 Type B1 necrotic reactions. 8.5 Type B2 reactions: immunotoxicity. 8.6 Type B3 reactions: role of metabolism in cancer. 8.7 Summary of biotransformational toxicity. Appendix A: Methods in Drug Metabolism. A.1 Introduction. A.2 Analytical techniques. A.3 Human liver microsomes. A.4 Human hepatocytes. A.5 Human cell lines. A.6 Heterologous recombinant systems. A.7 Animal model developments in drug metabolism. A.8 Toxicological metabolism-based assays. A.9 In silico studies. A.10 Summary. Appendix B. Metabolism of Major Illicit Drugs. B.1 Introduction. B.2 Opiates. B.3 Cocaine. B.4 Hallucinogens. B.5 Amphetamines. B.6 Cannabis. B.7 Dissociative anaesthetics. Appendix C. Examination Techniques. C.1 Introduction. C.2 A first-class answer. C.3 Preparation. C.4 The day of reckoning. Appendix D. Summary of Major CYP Isoforms and their Substates, Inhibitors and Inducers. Suggested Further Reading. Index.

Read more less

Book SynopsisWritten by a team of international experts, this book provides an authoritative overview and practical guide to the molecular biology and genetic basis of haematologic cancers including leukemia.Table of ContentsList of contributors xi Preface xiii 1 The myelodysplastic syndromes 1 Cristina Mecucci, Valeria Di Battista and Valeria Nofrini Introduction 1 Predisposing conditions 2 Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) 2 Severe congenital neutropenia (SCN) 5 Poikiloderma with neutropenia 6 Familial MDS/AML 6 Shwachman–Diamond syndrome (SDS) 7 Dyskeratosis congenita (DKC) and telomere syndromes 8 Fanconi anaemia (FA) 11 Down syndrome 12 Cytogenetics 12 Loss of Y chromosome (–Y) and del(11q) 13 Del(20q) 15 idic(X)(q13) 15 Del(17)(p13)/i(17q) 15 Del(12p) 16 Trisomy 8 16 Rare trisomies: +6, +13, +14, +15, +16, +19, +21 16 Monosomy 7 and del(7q) 17 Rare monosomies 19 Unbalanced translocations involving 1q 19 t(17;18)(p10;q10) 20 Rare or sporadic balanced translocations 20 Complex karyotypes 22 Chromosome 5q deletions 23 Somatic mutations 31 Oncogenes and tumour suppressor genes 31 Mutations of genes involved in epigenetic modulation 39 Mutations of genes involved in the spliceosome machinery 45 Rare gene mutations in myelodysplastic syndromes 48 Epigenetics 49 DNA methylation 50 Histone modifications 52 RNA 53 Conclusion 54 References 54 2 Molecular genetics of the myeloproliferative neoplasms 80 Philip A. Beer Introduction 80 Overview of the different types of mutation found in MPN patients 80 Acquired mutations in cytokine signalling pathways 82 Acquired mutations in pathways controlling transcriptional regulation 84 Acquired mutations associated with transformation to advanced-phase disease 87 Inherited predisposition to clonal MPNs 87 Inherited non-clonal disorders that phenocopy distinct MPNs 87 Polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) 88 Acquired mutations in cytokine signalling pathways (Table 2.3) 89 Acquired mutations in pathways controlling transcriptional regulation (Table 2.4) 95 Acquired mutations associated with progression to advanced and blastic-phase disease 101 Inherited predisposition to clonal MPNs 103 Inherited non-clonal disorders that phenocopy distinct MPNs 104 Principles and clinical utility of laboratory testing 107 Chronic eosinophilic leukaemia 109 Acquired mutations in cytokine signalling pathways 109 Acquired mutations in pathways controlling transcriptional regulation 113 Acquired mutations associated with progression to advanced and blastic-phase disease 113 Inherited predisposition to clonal MPNs 113 Inherited non-clonal disorders that phenocopy distinct MPNs 114 Principles and clinical utility of laboratory testing 114 Neoplastic mast cell disease 115 Acquired mutations in cytokine signalling pathways 116 Acquired mutations in pathways controlling transcriptional regulation 118 Acquired mutations associated with progression to advanced and blastic-phase disease 118 Inherited predisposition to clonal MPNs 119 Inherited non-clonal disorders that phenocopy distinct MPNs 119 Principles and clinical utility of laboratory testing 120 References 121 3 Acute myeloid leukaemia 133 Matthew L. Smith and Thomas McKerrell Introduction 133 AML classification 134 Cytogenetic aberrations 135 Fusion genes arising from structural rearrangements 135 Monosomies 148 Complex and monosomal karyotypes 148 Trisomies 148 Double minute chromosomes 151 Normal karyotype – is it really normal? 151 Altered gene expression 152 EVI1 152 BAALC 153 MN1 153 ERG 154 SET 154 BRE 154 WT1 154 miRNA genes 154 Diagnosis and classification of AML 155 Current risk stratification of AML patients: European LeukemiaNet (ELN) guidelines 156 Therapeutic regimens in AML 158 Management of younger adults aged 18–60 years 159 Older AML patients (aged >60 years) 159 Novel agents 160 Monitoring response to therapy (MRD) 160 The genomics of AML 161 Clonal evolution of AML 161 Established recurrent mutations in AML 163 Novel recurrent mutations in AML 173 Emerging concepts and future directions 179 Age-related clonal haematopoiesis (ARCH) 179 Application of genomic technologies to the diagnosis of AML 179 Conclusion 181 Mini-glossary 183 References 184 4 Molecular genetics of paediatric acute myeloid leukaemia 203 Marry van den Heuvel-Eibrink, Jasmijn D.E. de Rooij and Christian Michel Zwaan Clinical introduction 203 Epidemiology of AML 203 Diagnostic approach 204 Treatment and outcome 205 Relevant molecular and genetic aberrations in paediatric AML 206 Type I/II aberrations and their non-random associations 206 Relevance of type I/II aberrations for outcome and stratification of paediatric AML treatment 209 Epigenetic modifiers and hydroxymethylation pathway mutations 212 Further strategies 213 Further genomic approaches to unravelling the biology of paediatric AML 213 Molecularly targeted therapy 214 Conclusion 215 References 215 5 Acute lymphoblastic leukaemia 223 Anna Andersson, Anthony V. Moorman, Christine J. Harrison and Charles Mullighan Introduction 223 Chromosomal aberrations in BCP-ALL 224 High hyperdiploidy 227 t(12;21)(p13;q22)/ETV6-RUNX1 232 t(1;19)(q23;p13)/TCF3-PBX1 233 t(17;19)(q22;p13)/TCF3-HLF 234 Hypodiploidy 234 11q23/KMT2A (MLL) gene rearrangements 236 t(9;22)(q34;q11.1)/BCR-ABL1 237 Intrachromosomal amplification of chromosome 21 (iAMP21) 238 Complex karyotype 239 Submicroscopic genetic alterations in BCP-ALL 240 Alteration of transcription factors in BCP-ALL 241 CRLF2 rearrangements and Janus kinase mutations in ALL 242 BCR-ABL1-like or Ph-like ALL 243 ERG-altered ALL 245 Genetic rearrangements in T-lineage ALL 245 TAL1/LMO2 rearranged T-ALL 247 TLX1/TLX3 rearranged T-ALL 248 Early T-cell precursor ALL 249 Other T-ALL genetic subtypes: MLL rearranged and PICALM-MLLT10 250 Relapsed ALL 251 Future directions 252 References 252 6 The genetics of mature B-cell malignancies 265 Jonathan C. Strefford, Jude Fitzgibbon, Matthew J.J. Rose-Zerilli and Csaba Bödör Introduction 265 Chronic lymphocytic leukaemia 266 Immunoglobulin heavy-chain variable region gene mutational status 267 Chromosomal banding and interphase molecular cytogenetics 268 Copy number alterations 269 Deletions of 13q14 269 Trisomy 12 272 Deletions of 11q24 and mutations of ATM 273 Deletions of 17p13 and mutations of TP53 275 Other copy number alterations in CLL 276 Genome complexity and chromothripsis 277 Novel mutations in patients with CLL 279 NOTCH1 280 SF3B1 281 Other genes 282 Novel genetic mutations in clinical practice 282 Germinal centre lymphomas 284 Follicular lymphoma 286 Diffuse large B-cell lymphoma 293 Conclusions and future perspectives 296 Acknowledgements 299 References 299 7 The genetics of chronic myelogenous leukaemia 312Philippa C. May, Jamshid S. Khorashad, Mary Alikian, Danilo Perrotti and Alistair G. Reid Introduction 312 Clinical features 313 The structure and physiological function of BCR and ABL1 316 The structure of the BCR-ABL1 fusion gene 317 Mechanisms of BCR-ABL1-induced oncogenesis 319 Potential mechanisms underlying the genesis of CML 320 CML blast crisis transformation 321 Tyrosine kinase inhibitor (TKI) therapy 325 The genetic basis of TKI resistance 326 Novel therapeutic approaches 330 Genetics in patient management 332 Cytogenetic and molecular cytogenetic monitoring 332 Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) 334 BCR-ABL1 mutation analysis 337 Conclusion 338 References 339 Index 359

Read more less

Book SynopsisThis comprehensive guide helps health care professionals use genetics in managing patients at risk for, or already diagnosed with, common cancers. It offers health care professionals a framework for counseling patients, families, and colleagues about the availability, benefits, and limitations of the new technologies for genetic risk assessment.Trade Review"I refer to [this book] frequently and almost feel as if Dr. Offit was in the consulting room. I urge oncologists and other professionals providing cancer risk counseling to read this book and keep it at hand for convenient reference." (Annals of Oncology) "This is an excellent textbook ... it will be on my list of recommended reading for students...." (Human Genetics, May 2000) "This is an excellent textbook encompassing a wealth of experience." (Human Genetics, No. 106, 2000)Table of ContentsClinical Cancer Genetics and Risk Counseling. Hereditary and Acquired Risks for Cancer. Cancer as a Genetic Disorder. The Common Hereditary Cancers. Other Cancer Predisposition Syndromes. Quantitative Methods in Cancer Risk Assessment. Laboratory Methods of Cancer Genetic Testing. Genetic Testing in the Management of Patients with Cancer. Reproductive Counseling for Cancer Patients and Families. Psychological, Ethical, and Legal Issues of Cancer Risk Counseling. Glossary. Appendices. Index.

Read more less

Book SynopsisPresents stem cells and gene therapy together in one comprehensive volume. it also addresses the major advances in stem cell biology research and the many applications of this research in the development of novel molecular therapies.Table of ContentsStem Cell Systems: Basic Principles and Methodologies (S. Nilsson & P. Quesenberry). Cytokine/Growth Factor Responsiveness of Early Hemopoietic Progenitor Cells (A. Burgess). Molecular Mechanisms Controlling the Cell Cycle and Proliferation-Differentiation Interrelationships (G. Stein, et al.). Stem Cell Transcription (S. Weissman & A. Perkins). Hematopoietic Stem Cells: Proliferation, Purification and Clinical Applications (R. Pettengell & M. Moore). Delivery Systems for Gene Therapy: The Adenovirus (T. Shenk). Gene Transfer to Muscle and Spinal Cord Using Herpes Simplex Virus-Based Vectors (J. Huard, et al.). Herpes Virus Vectors (X. Breakefield, et al.). Delivery Systems for Gene Therapy: Adeno-Associated Virus (G. Kroner-Lux, et al.). Delivery Systems for Gene Therapy: Adeno-Associated Virus 2 (A. Srivastava). Ribozyme Gene Therapy Targeting Stem Cells for Human Immunodeficiency Virus Infection (A. Ho, et al.). Elements of DNA Vaccine Design (M. Caufield & M. Liu). Development of Gene Therapy for Gaucher Disease (J. Barranger, et al.). Clinical Applications of Gene Therapy: Correction of Genetic Disease Affecting Hematopoietic Cells (J. Medin, et al.). Gene Therapy for Hemophilia (K. High). Clinical Applications of Gene Therapy: Anemias (G. Atweh & B. Forget). Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents (T. Licht, et al.). Clinical Applications of Gene Therapy: Brian Tumors (K. Culver & J. Van Gilder). Clinical Applications of Gene Therapy: Cardiovascular Disease (J. Fox). Applications of Gene Therapy to Neurological Diseases and Injuries (D. Choi-Lundberg & M. Bohn). Index.

Read more less

Book SynopsisThis book examines the ethical, legal, and social implication of pharmacogenomics. Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care.Trade Review"The discussion of societal, legal, economic, and governmental issues go well beyond the sphere of pharmogenomics." (American Journal for Medical Genetics, September 1, 2005) "...indispensable guide...as timely as it can be...an impressive multidisciplinary analysis...a 'must read'..." (Bioethics, Vol 18(4), August 2004) "…Pharmacogenomics is highly recommended for anyone with an interest in the field…. Given this book's uniqueness…libraries at any institution teaching pharmcogenomics should have a copy of this book.” (Journal of Pharmacy Technology, Sept/Oct 2003) "...well written, clear, and informative...a restrained sense of excitement...permeates throughout...clearly...a solid contribution to the discourse." (Nature Biotechnology, May 1, 2003) "...chapters offer fascinating glimpses into fields that may not be familiar to geneticists, genomicists, or clinicians...they will be informative...and provide a reminder that many people outside this field are going to be paying a lot of attention as discoveries...are reported." (New England Journal of Medicine, July 24, 2003) "...an excellent summary of aspects of phamacogenomics...a solid reference for those working in the field and a unique textbook for those new to the subject area." (Clinical Chemistry, Vol. 49, No. 9) "...a welcome addition to the growing body of literature...highly recommended for anyone with an interest in the field...should be required reading for anyone conducting pharmacogenomic research and for all clinicians who use pharmacogenomics..." (Journal of Pharmacy Technology, Vol. 19September/October 2003) "...addresses the ethical, legal, and social implications of the individualized medicine that pharmacogenomics stands to create..." (Genetic Engineering News, Vol 23(14), 2003)Table of ContentsForeword (F. Collins). Preface. PART I: INTRODUCTION: SCIENCE AND SOCIETY. Public Attitudes About Pharmacogenomics (M. Rothstein, et al.). Pharmacogenomics: Pharmacology and Toxicology in the Genomics (H. Mohrenweiser). The Implications of Population Genetics for Pharmacogenomics (C. Hanis). PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS. Genome Research and Minorities (H. Greely). Drug Development Strategies (P. Manasco & T. Arledge). Drug Development, Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman). Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally, et al.). PART III: CLINICAL APPLICATIONS. Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky). Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman). Medical Liability for Pharmacogenomics (L. Palmer). The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation (D. Brushwood). PART IV: THE SOCIAL DIMENSION. Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). Pharmacogenomics and the Social Construction of Identity (M. Foster). Pharmacogenomics: Considerations for Communities of Color (L. Nsiah-Jefferson). Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson). PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein). Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein). Index.

Read more less

Book SynopsisAs with all biotechnologies in the midst of rapid growth, nutrigenomics faces ethical, legal, and social implications that are likely to affect the public and the medical community. This title identifies and examines the anticipated risks and expected benefits of nutrigenomics from an ethical perspective.Trade Review"…a worthy acquisition for any medical library…along with students and instructors in nutrition and health care." (CHOICE, June 2007) "This concise overview of nutritional genomics covers a variety of topics surrounding this controversial topic." (Doody's Health Services)Table of ContentsPreface. Acknowledgments. 1 NUTRITIONAL GENOMICS: OPPORTUNITIES AND CHALLENGES. 1.1 Introduction. 1.2 What is Nutritional Genomics? 1.3 Methodology and Approach of this Book. 1.4 Opportunities and Challenges for Nutrigenomics. 1.4.1 Improved health. 1.4.2 Personalized dietary advice. 1.4.3 Improved diet. 1.4.4 More development of health-enhancing food products. 1.4.5 Consumer empowerment. 1.4.6 Reducing health disparities. 1.4.7 Health care savings. 1.5 Challenges and a Road Map of This Book. References. 2 THE SCIENCE OF NUTRIGENOMICS AND NUTRIGENETICS. 2.1 Introduction. 2.2 The Scientific Context. 2.2.1 Nutrigenomics. 2.2.2 Nutrigenetics. 2.3 The Case of MTHFR. 2.4 Room for Improvement. 2.4.1 Study design. 2.4.2 Epigenetics. 2.4.3 SNPs and haplotypes. 2.4.4 Dietary intake assessment. 2.4.5 Biomarkers. 2.4.6 Susceptibility and predictions. 2.4.7 Analytical and clinical validity. 2.4.8 Clinical utility. 2.5 Science and Technology Assessment. 2.6 Conclusion. References. 3 THE ETHICS OF NUTRIGENOMIC TESTS AND INFORMATION. 3.1 Introduction. 3.2 Ethical Principles. 3.3 Nutrigenomics Testing in the Clinical Setting. 3.3.1 Informed consent. 3.3.2 Confidentiality. 3.3.3 Secondary information. 3.3.4 Families. 3.3.5 Genetic testing of children and adolescents. 3.4 Use of Nutrigenomics Information for Research. 3.5 Use of Nutrigenomics Information by Private Third Parties. 3.5.1 Insurance. 3.5.2 Employment. 3.5.3 Legal and social responses to fears of discrimination. 3.6 Conclusion. References. 4 ALTERNATIVES FOR NUTRIGENOMIC SERVICE DELIVERY. 4.1 Introduction. 4.2 Considerations for Nutrigenomic Service Delivery. 4.2.1 Strength of the science. 4.2.2 Regulatory environment. 4.2.3 Human resource capacity and professional competence. 4.2.4 Funding policy. 4.2.5 Professional politics and culture. 4.2.6 Consumers and patients. 4.3 Four Alternative Models. 4.3.1 Consumer model. 4.3.2 Health practitioner model. 4.3.3 Blended models. 4.3.4 Public health model. 4.4 Conclusion. References. 5 NUTRIGENOMICS AND THE REGULATION OF HEALTH CLAIMS FOR FOODS AND DRUGS. 5.1 Introduction. 5.1.1 Genetic tests, service delivery, and genetic antidiscrimination. 5.2 Food Categories: Functional Foods, Nutraceuticals, Medicinal Foods, and Dietary Supplements. 5.2.1 Functional foods. 5.2.2 Nutraceuticals. 5.2.3 Medical or medicinal foods. 5.2.4 Dietary supplements. 5.3 Health-Related Claims Associated with Foods Compared to Drugs. 5.3.1 Structure–function claims. 5.3.2 Health claims. 5.3.3 Medical food claims. 5.3.4 Disease risk reduction claims. 5.4 Nutrigenomic Information and the Regulation of Foods Compared to Drugs. 5.4.1 The regulation of foods. 5.4.2 The regulation of drugs. 5.5 Food and Drug Regulations in Japan, the United States, and Canada. 5.5.1 Japan. 5.5.2 United States. 5.5.3 Canada. 5.6 Conclusion. References. 6 NUTRIGENOMICS: JUSTICE, EQUITY, AND ACCESS. 6.1 Introduction. 6.2 Industrialized Country Context. 6.2.1 Individualized nutrigenomic testing. 6.2.2 Population-based nutrigenomics. 6.3 Developing Country Context. 6.3.1 Individualized nutrigenomic testing. 6.4 Nutrigenomics and Intellectual Property. 6.4.1 An issue of access to scientific information. 6.5 Conclusion. References. 7 CONCLUSIONS AND RECOMMENDATIONS. 7.1 Introduction. 7.1.1 Nutrigenomic science. 7.1.2 Nutrigenomics and health information management. 7.1.3 Nutrigenomic service delivery. 7.1.4 Regulation of nutrigenomics. 7.1.5 Access and equity. 7.2 A Final Word. Index.

Read more less

Book SynopsisPopulation Genetics of Multiple Loci F.B. Christiansen University of Aarhus, Denmark "This is a very beautiful and powerful study of an area that Christiansen has dominated for many years. " - Marcus Feldman, Stanford University, USA Population genetics thrives on the constant interaction between theoretical and empirical knowledge.Trade Review"...a significant contribution to mathematical population genetics...recommended" --Monatshefte fur Mathematik, Vol 131/2, 2000 "This book makes an excellent contribution." --Genetical Research, Vol 75, 2000Table of ContentsInteractions among Genes. RECOMBINATION AND SEGREGATION. Random Mating: Sexes Equal. Random Mating: Sex Difference. Inbreeding: Partial Selfing. Migration and Mixing. Phenotypic Variation. SELECTION. Viability Selection. Symmetric Viability Selection. Fertility Selection. Mutation and Selection. Migration and Selection. Evolution of Recombination. Glossary. References. Index.

Read more less

Book SynopsisWith the advent of the Human Genome Project, the new genetics has moved to the cutting edge of science and medicine. The development and use of such genetics will have a profound impact on our understanding of disease and behaviour.Table of ContentsIntroduction: Sociological Perspectives on The New Genetics: An Overview: Peter Conrad and Jonathan Gabe. Part I: Structure and Production of Genetic Knowledge:. 1. Genes as Drugs: The Social Shaping of Gene Therapy and The Reconstruction of Genetic Disease: Paul Martin. 2. Experts as 'Storytellers' In Reproductive Genetics: Exploring Key Issues: Elizabeth Ettorre. 3. The Human Drama of Genetics: 'Hard' and 'Soft' Media Representations of Inherited Breast Cancer: Lesley Henderson and Jenny Kitzinger. Part II: The Social Meanings of Genetics:. 4. Waiting For The Cure: Mapping The Social Relations of Human Gene Therapy Research: Alan Stockdale. 5. Doing The Right Thing: Genetic Risk and Responsibility: Nina Hallowell. 6. There's This Thing In Our Family: Predictive Testing and The Construction of Risk For Huntington Disease: Susan Cox and William Mckellin. Part III: The Social Impact and Implications of Genetics:. 7. Defining The 'Social': Towards An Understanding of Scientific and Medical Discourses on The Social Aspects of The New Human Genetics: Sarah Cunningham-Burley and Anne Kerr. 8. Losing The Plot? Medical and Activist Discourses of The Contemporary Genetics and Disability: Tom Shakespeare. 9. DNA Identification and Surveillance Creep: Dorothy Nelkin and Lori Andrews. Notes on Contributors. Index.

Read more less

Book SynopsisAre reproductive and genetic technologies racing ahead of a society that is unable to establish limits to their use? This book examines the case of preimplantation genetic diagnosis (PGD), the procedure used to prevent serious genetic disease by embryo selection, and the so-called "designer baby" method.Trade Review"The book is a source of valuable messages; it provides enlightening perspectives on the political, moral and ethical aspects of PGD and highlights intriguing philosophical questions... Born and Made: An Ethnography of Preimplantation Genetic Diagnosis will constitute a valuable resource for professionals working in a variety of disciplines converging on the multidisciplinary field of assisted reproduction; at the same time, the book will benefit those who consider, or are referred for, assisted reproduction techniques."--Richard A. Stein, TRENDS in Endocrinology and MetabolismTable of ContentsList of Figures ix Acknowledgments xi Preface xv Introduction: Babies by Design? 1 Chapter 1: What Is PGD? 25 Chapter 2: Studying PGD 75 Chapter 3: Getting to PGD 94 Chapter 4: Going Through PGD 132 Chapter 5: Moving On from PGD 163 Chapter 6: Accounting for PGD 196 Conclusion: PGD Futures? 218 Appendix 231 References 233 Index 249

Read more less

Book SynopsisTrade Review"Winner of the Pfizer Award, History of Science Society""Winner of the Cheiron Book Prize, Cheiron: The International Society for the History of Behavioral & Social Sciences""One of Science News' Favorite Science Books of 2018""I suspect this bold, dauntingly well-documented book will prove difficult to dismiss."---David Dobbs, Nature"By following the technologies of paperwork and data collection, Porter has unearthed a radically new history of human genetics, one that evokes not the double helix but the humble filing cabinet."---Emily M. Kern, Science"Fascinating but scary. Genetics in the Madhouse . . . uses date collection in psychiatric hospitals to show the stages when research straddles subjectivity and science."---Liz Else and Simon Ings, New Scientist"Porter takes a fascinating look at early attempts to tame unruly minds with big data and statistics."---Bruce Bower, Science News"Deeply researched and deftly argued."---Gregory Radick, Times Literary Supplement"[An] absorbing account of the role played by mental illness studies in gaining an early understanding of human heredity."---Robin McKie, The Observer"Genetics in the Madhouse provides a fascinating examination of investigations of human heredity, conducted long before DNA could be studied in laboratories."---Glenn Altschuler, Philadelphia Inquirer"Genetics in the Madhouse has the power to inspire, to captivate and to stimulate further research."---Nicholas P. Hatton, Medical History"Porter commands an impressive array of languages, and where his own knowledge falters, he has employed assistance to allow him to survey other sources that would otherwise have remained out of reach."---Andrew Scull, Brain Journal of Neurology"Porter has read voluminously in the secondary literature historians of psychiatry have produced. But more importantly, having done so, he has engaged in a positively prodigious amount of work in the archives. One can only admire the persistence and the diligence with which he has combed through an extraordinary array of materials . . . Genetics in the Madhouse is gracefully written, and Porter only occasionally gets bogged down in the minutiae of the archival materials he has spent so much time exploring."---Andrew Scull, Brain"Porter shows that the population view of mental illness persisted throughout the history of the asylum and flowed logically into the era of eugenics. And he also illustrates that the history of madness helps expand the history of genetics beyond a narrow view of genes. . . . His history makes it impossible to continue the disconnect between the data of the past and the assertions of the present."---Laura D. Hirshbein, The Common Reader

Read more less

Book SynopsisTrade Review"Winner of the Pfizer Award, History of Science Society""Winner of the Cheiron Book Prize, Cheiron: The International Society for the History of Behavioral & Social Sciences""One of Science News' Favorite Science Books of 2018"

Read more less

Book SynopsisTrade Review"Aktipis takes an evolutionary approach to cancer, tracing the ways cells ‘cheat’ natural selection and showing how the human body evolved to outsmart many of those threats. She invites readers to put themselves in the role of a cancer cell and learn about the ways in which the disease and the history of human existence are intertangled."---Erin Blakemore, Washington Post"Darwinian approach to evolution of cancer and cancer-resistance. Brilliant book, up there with Nesse & Williams."---Richard Dawkins on Twitter"The Cheating Cell reads like a deep and personal hypothesis coming from a researcher who has spent over a decade studying the evolutionary foundations of cancer."---David C. S. Filice, Evolution"The Cheating Cell makes for fascinating reading and forces a radical reconsideration of what cancer is and how we should deal with it."---Leon Vlieger, The Inquisitive Biologist

Read more less

Book SynopsisPresenting a wide array of perspectives, this book emphasizes the need to ensure that research into genetics research does not result in discrimination against people on the basis of their DNA.Trade ReviewBringing the concerns of different communities together in a single volume makes it possible to appreciate the mosaic of human issues more fully and forces us to anticipate the challenges that may arise-and that will require our attention-as the genetic revolution proceeds... A much needed antidote to the current genetic hoopla. -- Doris Teichler Zallen Journal of the American Medical Association A cautious look at the effects of genetic discoveries on society... The issues raised by this book are valid, and all scientists should be aware of them. I often found myself nodding in agreement. -- Jeffrey C. Long New England Journal of Medicine The authors present several thought-provoking issues in regard to prenatal genetic screening and selective abortion. It's a great contribution to the field. -- Fernando I. Rivera Contemporary Sociology This book superbly and successfully fills its purpose-to show the need for dialogue between researchers, health care professionals, communities, and individuals regarding various aspects of genetic technology. Choice 2003

Read more less

Book SynopsisEdited by leaders in the field, written by experts from around the globe, and brimming with full-color illustrations, Genomic Medicine is an indispensable guide to the full potential of the DNA-based transformation of medicine.Trade ReviewAn indispensable guide to the full potential of the DNA-based transformation of medicine. Human Reproduction and Genetic Ethics The editors have assembled a fine set of short, readable and highly authoritative articles by eminent authors. The book is beautifully produced and will give an accessible entry into genetic medicine to its target audience of non-specialist clinicians. Readers of this journal will need no persuading of the fascination and ever growing importance of genetic medicine and these themes are well communicated. -- Andrew P. Read Human Genetics 2004Table of ContentsForewordPrefaceList of Contributors GlossaryChapter 1. Getting Ready for Gene-Based MedicineChapter 2. Genomic Medicine – A PrimerChapter 3. Genetic TestingChapter 4. Population Screening in the Age of Genomic Medicine Chapter 5. Inheritance and Drug Response Chapter 6. Pharmacogenomics – Drug Disposition, Drug Targets, and Side EffectsChapter 7. Pharmacogenetics in the Laboratory and the Clinic Chapter 8. Hereditary Colorectal CancerChapter 9. Alzheimer's Disease and Parkinson's DiseaseChapter 10. Molecular Diagnosis of the Hematologic CancersChapter 11. Breast and Ovarian CancerChapter 12. Cardiovascular DiseaseChapter 13. Ethical, Legal, and Social Implications of Genomic MedicineChapter 14. Genomics as a Probe for Disease Biology Chapter 15. Welcome to the Genomic EraIndex

Read more less

Book SynopsisWith Tay-Sachs, cystic fibrosis, and sickle cell disease as a powerful backdrop, the authors provide a glimpse into a diverse America where racial ideologies, cultural politics, and conflicting beliefs about the power of genetics shape disparate health care expectations and experiences.Trade ReviewConcise and well-argued... essential reading for anyone interested in genetics, disease, and the meaning of race. Science 2006 Practitioners of the future will have to take these separate histories into account as this new era unfolds. -- Doris Teichler Zallen, PhD JAMA 2006 Fascinating. -- Jackie Leach Scully Social History of Medicine 2007 Perfectly suited for use in teaching the history of medicine and health... At once concise, readable, and demanding in its parsimony. It should not be missed by anyone who cares about the emerging shape of health care in the age of genomic medicine. -- Christopher Crenner Journal of the History of Medicine 2008 Offers interesting information and pertinent discussions... The book deserves to be read by a large public. -- Michel Morange Isis 2008 The Troubled Dream of Genetic Medicine brings into focus intriguing concepts at the intersection of science and society... This book ought to encourage others to produce biosocial histories of this kind. -- Abidemi Adegbola, M.D. Child and Adolescent Psychiatry 2009Table of ContentsAcknowledgmentsIntroduction: Ethnic Symbols in Conflicted Times1. Eradicating a ''Jewish Gene'': Promises and Pitfalls in the Fight against Tay-Sachs Disease2. Risky Business in White America: Gene Therapy and Other Ventures in the Treatment of Cystic Fibrosis3. A Perilous Lottery for the Black Family: Sickle Cells, Social Justice, and the New Therapeutic GambleConclusion: Dreams amid DiversityNotesGlossaryIndex

Read more less

Book SynopsisConcluding with a cautionary call for increased regulation, Reprogenetics introduces fact, history, and reason into a public discussion of complex and vexing issues.Trade ReviewAn essential reference, this also will extend into classroom discussion and debates. Midwest Book Review 2007 A useful addition to the library of anyone interested in reprogenetics and particularly the future of legislation and policy on research and application of reprogenetic technology. -- Constance Perry, Ph.D. Metapsychology 2008Table of ContentsList of ContributorsPrefacePart I: The Historical and Regulatory LandscapeChapter 1. On Drawing Lessons from the History of EugenicsChapter 2. Governmental Regulation of Genetic Technology, and the Lessons LearnedChapter 3. Oversight of Assisted Reproductive Technologies: The Last Twenty YearsPart II: Ethical Issues in ReprogeneticsChapter 4. Market Transactions in Reprogenetics: A Case for RegulationChapter 5. Stem Cells, Clones, Consensus, and the LawPart III: International Regulation of Reprogenetics Chapter 6. The Governance of Reprogenetic Technology: International ModelsChapter 7. Regulating Reprogenetics in the United KingdomChapter 8. The Evolution of Public Policy on Reprogenetics in CanadaPart IV: Regulating Reprogenetics in the United StatesChapter 9. A Brief History of Public Debate about Reproductive Technologies: Politics and CommissionsChapter 10. Possible Policy Strategies for the United States: Comparative LessonsChapter 11. The Development of Reprogenetic Policy and Practice in the United States: Looking to the United KingdomChapter 12. Reprogenetics and Public Policy: Reflections and RecommendationsIndex

Read more less

Book SynopsisSharon R. Kaufman examines the quandary of patients, families and doctors not knowing the point where enough medical treatment becomes too much treatment. A hidden chain of drivers among science, industry, new technology, and insurance spur this quandary, serving to obscure the ability to identify the difference between extraordinary and ordinary medicine.Trade Review“Medical anthropologist Kaufman bravely delves into the heartbreaking predicament of modern medicine: ‘getting the medicine we wish for but then having to live with the unsettling and far-ranging consequences.’ … Kaufman is at her best when focusing on the heartbreaking dilemma of patients dealing with the consequences of ordinary medicine, such as an elderly patient who must choose between lifesaving treatments or palliative care, facing repeated hospital visits regardless of the choice. Kaufman calls for no less than making the ethics of medicine the ‘preeminent topic of our national conversation about health care reform.’” * Publishers Weekly *(Starred Review) “What makes Kaufman's analysis distinctive is the way she demonstrates the effects of Medicare policy on treatment benefits—namely, if a patient on Medicare is eligible for treatment, providers are often willing to supply it. But the author notes that this way of thinking has led us to stop examining issues around quality of life, obligations to our families, and the inevitable prospect that we will die. Health-care professionals, students of medical ethics, and others interested in the actions that frame American medicine will find this a thought-provoking read." -- Aaron Klink * Library Journal *“If Gawande’s is the voice of comfort, and simple yet vital solutions, Sharon Kaufman’s brings her characteristic analytic and ethical precision, eschewing easy answers for an assessment of the structural density of our current predicament. Anyone who has read her earlier book on end-of-life care in American hospitals, And a Time to Die: How American Hospitals Shape the End of Life, will be familiar with her tremendous ability to narrate the ambiguities of American medicine as it unfolds on the ground via the stories of people who are caught up in its contradictions.” -- Julie Livingston * Public Books *"The elegant part of Kaufman’s analysis—of a kind maybe only a sharp-eyed anthropologist with a wide lens can provide—concerns the way we all become unwitting victims of the chain, wrapped tightly around us.... Is there any good news here? Yes, Sharon Kaufman has written a wonderful, necessary, and readable book, and that is a start." -- Daniel Callahan * Hastings Center Report *"Fascinating.... The book is written in a lucid and highly readable style, case studies of patients bringing the ‘health care system’ vividly alive through thick description.... The ethical dilemmas, small and large simultaneously, gripped me such that on two consecutive readings I found myself sitting up late into the night unable to put it down." -- Susan Pickard * Social History of Medicine *"Kaufman delivers a haunting and provocative meditation on the peculiarly American obsession with highly technologized longevity. Through a combination of historical analyses of debates in health policy and health economics, bioethical argumentation, and powerful ethnographic examples, Kaufman meticulously demonstrates the rise over the past few decades of what she calls ordinary medicine.... Kaufman’s book constitutes an important and troubling addition to current bioethical debates on health financing and the distribution of medical resources. At its heart, this book seems to be about how and why US health care costs have spiraled out of control—a topic of great timeliness and political interest." -- Katherine A. Mason * American Ethnologist *"A must read for all practitioners and people experiencing the end of life.... Kaufman does a good job discussing the four outside issues that impact medicine today: the biomedical research industry, which pours out expensive new treatments; the determination of what treatments will be ordered according to what insurance or Medicare will reimburse for; evidence supporting a treatment’s use, causing it to become standard care for all; and the ethical imperative that if something is standard, everyone should receive it. Kaufman also provides several scenarios and an extensive bibliography. This book should be required reading for every health care provider. Highly recommended. Upper-division undergraduates through professionals/practitioners" -- S. C. Grossman * Choice *"The strengths of this revealing study derive from Kaufman’s analysis of the chain of drivers that creates unprecedented growth in medical treatments; compelling evidence from case studies; multiple perspectives of physicians and other health care personnel, patients, and their families; and the questions raised about drawing the line. This book will create a deeper understanding of the expanding possibilities for medical treatments and the implications for the health care system." -- Joanne McCloskey * Journal of Anthropological Research *"[T]his is a book whose moral passion is palpable, and admirable for just that reason, as well as for its excellent scholarship. Yet, it is Kaufman’s careful, insightful observations that carry us beyond her undeniably excellent analysis." -- David Schenck * Society *"Overall, Kaufman’s latest book is moving to read and sets out the dilemmas of aging and dying within the American healthcare system.... I would recommend that anthropologists and healthcare professionals read her book to reflect on the healthcare practices they are part of and observe." -- Erica Borgstrom * Anthropology and Medicine *Table of ContentsAcknowledgments ix Introduction. Diagnosing Twenty-First-Century Health Care 1 Part I: The Quandry and Unexamined Ordinariness of Twenty-First-Century Medicine 1. Ordinary Medicine in Our Aging Society: The Dilemma of Longevity 21 Part II. The Chain of Health Care Drivers 2. The Medical-Industrial Complex I: Evidence-Based Medicine, the Biomedical Economy, and the Ascendance of Clinical Trials 53 3. The Medical-Industrial Complex II: Access, Industry, and the Clincial Trials Phenomenon 79 4. "Reimbursement Is Critical for Everything": Medicare and the Ethics of Managing Life 99 Part III: Medicine's Changing Means and Ends 5. Standard and Necessary Treatments: The Changing Means and Ends of Technology 127 6. Family Matters: Kidneys and New Forms of Care 165 7. Influencing the Character of the Future: Prognosis, Risk, and Time Left 195 8. For Whose Benefit? Our Shared Quandary 217 Conclusion. Toward a New Social Contract? 238 Notes on the Research 249 Notes 255 Bibliography 285 Index 307

Read more less

Book SynopsisSharon R. Kaufman examines the quandary of patients, families and doctors not knowing the point where enough medical treatment becomes too much treatment. A hidden chain of drivers among science, industry, new technology, and insurance spur this quandary, serving to obscure the ability to identify the difference between extraordinary and ordinary medicine.Trade Review“Medical anthropologist Kaufman bravely delves into the heartbreaking predicament of modern medicine: ‘getting the medicine we wish for but then having to live with the unsettling and far-ranging consequences.’ … Kaufman is at her best when focusing on the heartbreaking dilemma of patients dealing with the consequences of ordinary medicine, such as an elderly patient who must choose between lifesaving treatments or palliative care, facing repeated hospital visits regardless of the choice. Kaufman calls for no less than making the ethics of medicine the ‘preeminent topic of our national conversation about health care reform.’” * Publishers Weekly *(Starred Review) “What makes Kaufman's analysis distinctive is the way she demonstrates the effects of Medicare policy on treatment benefits—namely, if a patient on Medicare is eligible for treatment, providers are often willing to supply it. But the author notes that this way of thinking has led us to stop examining issues around quality of life, obligations to our families, and the inevitable prospect that we will die. Health-care professionals, students of medical ethics, and others interested in the actions that frame American medicine will find this a thought-provoking read." -- Aaron Klink * Library Journal *“If Gawande’s is the voice of comfort, and simple yet vital solutions, Sharon Kaufman’s brings her characteristic analytic and ethical precision, eschewing easy answers for an assessment of the structural density of our current predicament. Anyone who has read her earlier book on end-of-life care in American hospitals, And a Time to Die: How American Hospitals Shape the End of Life, will be familiar with her tremendous ability to narrate the ambiguities of American medicine as it unfolds on the ground via the stories of people who are caught up in its contradictions.” -- Julie Livingston * Public Books *"The elegant part of Kaufman’s analysis—of a kind maybe only a sharp-eyed anthropologist with a wide lens can provide—concerns the way we all become unwitting victims of the chain, wrapped tightly around us.... Is there any good news here? Yes, Sharon Kaufman has written a wonderful, necessary, and readable book, and that is a start." -- Daniel Callahan * Hastings Center Report *"Fascinating.... The book is written in a lucid and highly readable style, case studies of patients bringing the ‘health care system’ vividly alive through thick description.... The ethical dilemmas, small and large simultaneously, gripped me such that on two consecutive readings I found myself sitting up late into the night unable to put it down." -- Susan Pickard * Social History of Medicine *"Kaufman delivers a haunting and provocative meditation on the peculiarly American obsession with highly technologized longevity. Through a combination of historical analyses of debates in health policy and health economics, bioethical argumentation, and powerful ethnographic examples, Kaufman meticulously demonstrates the rise over the past few decades of what she calls ordinary medicine.... Kaufman’s book constitutes an important and troubling addition to current bioethical debates on health financing and the distribution of medical resources. At its heart, this book seems to be about how and why US health care costs have spiraled out of control—a topic of great timeliness and political interest." -- Katherine A. Mason * American Ethnologist *"A must read for all practitioners and people experiencing the end of life.... Kaufman does a good job discussing the four outside issues that impact medicine today: the biomedical research industry, which pours out expensive new treatments; the determination of what treatments will be ordered according to what insurance or Medicare will reimburse for; evidence supporting a treatment’s use, causing it to become standard care for all; and the ethical imperative that if something is standard, everyone should receive it. Kaufman also provides several scenarios and an extensive bibliography. This book should be required reading for every health care provider. Highly recommended. Upper-division undergraduates through professionals/practitioners" -- S. C. Grossman * Choice *"The strengths of this revealing study derive from Kaufman’s analysis of the chain of drivers that creates unprecedented growth in medical treatments; compelling evidence from case studies; multiple perspectives of physicians and other health care personnel, patients, and their families; and the questions raised about drawing the line. This book will create a deeper understanding of the expanding possibilities for medical treatments and the implications for the health care system." -- Joanne McCloskey * Journal of Anthropological Research *"[T]his is a book whose moral passion is palpable, and admirable for just that reason, as well as for its excellent scholarship. Yet, it is Kaufman’s careful, insightful observations that carry us beyond her undeniably excellent analysis." -- David Schenck * Society *"Overall, Kaufman’s latest book is moving to read and sets out the dilemmas of aging and dying within the American healthcare system.... I would recommend that anthropologists and healthcare professionals read her book to reflect on the healthcare practices they are part of and observe." -- Erica Borgstrom * Anthropology and Medicine *Table of ContentsAcknowledgments ix Introduction. Diagnosing Twenty-First-Century Health Care 1 Part I: The Quandry and Unexamined Ordinariness of Twenty-First-Century Medicine 1. Ordinary Medicine in Our Aging Society: The Dilemma of Longevity 21 Part II. The Chain of Health Care Drivers 2. The Medical-Industrial Complex I: Evidence-Based Medicine, the Biomedical Economy, and the Ascendance of Clinical Trials 53 3. The Medical-Industrial Complex II: Access, Industry, and the Clincial Trials Phenomenon 79 4. "Reimbursement Is Critical for Everything": Medicare and the Ethics of Managing Life 99 Part III: Medicine's Changing Means and Ends 5. Standard and Necessary Treatments: The Changing Means and Ends of Technology 127 6. Family Matters: Kidneys and New Forms of Care 165 7. Influencing the Character of the Future: Prognosis, Risk, and Time Left 195 8. For Whose Benefit? Our Shared Quandary 217 Conclusion. Toward a New Social Contract? 238 Notes on the Research 249 Notes 255 Bibliography 285 Index 307

Read more less

Book SynopsisThis volume explores the latest techniques used by researchers to study directed evolution (DE) at each stage of the Design-Build-Test-Learn cycle.Table of ContentsPreface…Table of Contents…Contributing Authors…1. Designing Overlap Extension PCR Primers for Protein Mutagenesis: A Programmatic ApproachXiaofang Huang, Liangting Xu, Chuyun Bi, Zhao Lili, Zhang Limei, Xuanyang Chen, Shiqian Qi, and Shiqiang Lin2. Recombination of Single Beneficial Substitutions Obtained from Protein Engineering by Computer-Assisted Recombination (CompassR)Haiyang Cui, Mehdi D. Davari, and Ulrich Schwaneberg3. Non-Degenerate Saturation Mutagenesis: Library Construction and Analysis via MAX and ProxiMAX RandomizationAnupama Chembath, Ben P.G. Wagstaffe, Mohammed Ashraf, Marta M. Ferreira Amaral, Laura Frigotto, and Anna V. Hine4. Antha-Guided Automation of Darwin Assembly for the Construction of Bespoke Gene LibrariesP. Handal-Marquez, M. Koch, D. Kestemont, S. Arangundy-Franklin, and V.B. Pinheiro5. SpeedyGenesXL An Automated, High-Throughput Platform for the Preparation of Bespoke Ultra-Large Variant Libraries for Directed EvolutionJoanna C. Sadler, Neil Swainston, Mark S. Dunstan, Andrew Currin, and Douglas B. Kell6. Facile Assembly of Combinatorial Mutagenesis Libraries using Nicking MutagenesisMonica B. Kirby and Timothy A. Whitehead7. GeneORator: An Efficient Method for the Systematic Mutagenesis of Entire GenesLucy Green, Nigel S. Scrutton, and Andrew Currin8. Rapid Cloning of Random Mutagenesis Libraries using PTO-QuickStepPawel Jajesniak, Kang Lan Tee, and Tuck Seng Wong9. Construction of Strong Promoters by Assembling Sigma Factor Binding MotifsYonglin Zhang, Yang Wang, Jianghua Li, Chao Wang, Guocheng Du, and Zhen Kang10. Application of Restriction Free (RF) Cloning in Circular PermutationBoudhayan Bandyopadhyay and Yoav Peleg11. Site-Directed Mutagenesis Method Mediated by Cas9Wanping Chen, Wenwen She, Aitao Li, Chao Zhai, and Lixin Ma12. Directed Evolution of Transcription Factor-Based Biosensors for Altered Effector SpecificityLeopoldo Ferreira Marques Machado and Neil Dixon13. A Screening Method for P450 BM3 Mutant Libraries using Multiplexed Capillary Electrophoresis for Detection of Enzymatically Converted CompoundsAnna Gärtner, Gustavo de Almeida Santos, Anna Joëlle Ruff, and Ulrich Schwaneberg14. Directed Evolution of Glycosyltransferases by a Single-Cell Ultrahigh-Throughput FACS-Based Screening MethodYumeng Tan, Xue Zhang, Yan Feng, and Guangyu Yang15. Learning Strategies in Protein Directed EvolutionXavier F. Cadet, Jean Christophe Gelly, Aster van Noord, Frédéric Cadet, and Carlos G. Acevedo-RochaSubject Index List…

Read more less

Book SynopsisThis book discusses principles, methodology, and applications of microbiological laboratory techniques . It lays special emphasis on the use of various automated machines that are essential for medical microbiology and diagnostic labs. The book contains eleven major chapters. The first chapter describes the good lab practices which should be followed by the students in all biological, chemistry or microbiology laboratories. The next chapter describes manual and automated characterization of antibiotic resistant microbes, followed by a chapter on genomics based tools and techniques that are integral to research. Further chapters deal with other important techniques like immunology based techniques, spectrophotometry and its various types, MALDI-TOFF and microarrays, each with illustrations and detailed description of the protocols and applications. The book also gives certain important guidelines to the students about the planning the experiment and interpreting results. Table of Contents

Read more less

Book SynopsisThis volume offers readers an opportunity to learn about how genomes are sequenced, what discoveries have so far come out of this scientific revolution, and about the ethical dimensions of this advancing technology.Table of ContentsForeward: Still, The Genomic Revolution ix Acknowledgments xi Introduction: Welcome Back to the Genome xiii 1 From Mendel to Molecules 1 2 The Building Blocks of Gene Sequencing 31 3 Sequencing the Genome 47 4 The Next Generation 65 5 Making the Genome Safe 81 6 The Meanings of Genetic Diversity: Part I 121 7 The Meanings of Genetic Diversity: Part II 143 8 The Tree of Life: 4 Billion Years of Divergence 161 9 Sequencing the Small and Infamous: A Look at Metagenomics and Microbiomes 195 10 The World to Come: Agriculture 213 Conclusion: Don’t Believe the Hype (Including Ours) 245 Index 249

Read more less

Book SynopsisGenetic Analysis of Complex Diseases An up-to-date and complete treatment of the strategies, designs and analysis methods for studying complex genetic disease in human beings In the newly revised Third Edition of Genetic Analysis of Complex Diseases, a team of distinguished geneticists delivers a comprehensive introduction to the most relevant strategies, designs and methods of analysis for the study of complex genetic disease in humans. The book focuses on concepts and designs, thereby offering readers a broad understanding of common problems and solutions in the field based on successful applications in the design and execution of genetic studies. This edited volume contains contributions from some of the leading voices in the area and presents new chapters on high-throughput genomic sequencing, copy-number variant analysis and epigenetic studies. Providing clear and easily referenced overviews of the considerations involved in genetic analysis of compTable of ContentsList of Contributors xv Foreword xvii 1 Designing a Study for Identifying Genes in Complex Traits 1 William K. Scott, Marylyn D. Ritchie, Jonathan L. Haines,and Margaret A. Pericak-Vance Introduction 1 Components of a Disease Gene Discovery Study 3 Define Disease Phenotype 4 Clinical Definition 4 Determining that a Trait Has a Genetic Component 5 Identification of Datasets 5 Develop Study Design 5 Family-Based Studies 6 Population-Based Studies 6 Approaches for Gene Discovery 7 Analysis 7 Genomic Analysis 7 Statistical Analysis 8 Bioinformatics 8 Follow-up 8 Variant Detection 8 Replication 9 Functional Studies 9 Keys to a Successful Study 10 Foster Interaction of Necessary Expertise 10 Develop Careful Study Design 11 References 11 2 Basic Concepts in Genetics 13 Kayla Fourzali, Abigail Deppen, and Elizabeth Heise Introduction 13 Historical Contributions 13 Segregation and Linkage Analysis 13 Hardy–Weinberg Equilibrium 14 DNA, Genes, and Chromosomes 17 Structure of DNA 17 Genes and Alleles 19 Genes and Chromosomes 20 Genes, Mitosis, and Meiosis 22 When Genes and Chromosomes Segregate Abnormally 25 Inheritance Patterns in Mendelian Disease 25 Autosomal Recessive 25 Autosomal Dominant 25 X-linked Inheritance 28 Mitochondrial Inheritance 29 Y-linked 29 Genetic Changes Associated with Disease/ Trait Phenotypes 29 Mutations Versus Polymorphisms 29 Point Mutations 30 Sickle Cell Anemia 30 Achondroplasia 30 Deletion/Insertion Mutations 31 Duchenne and Becker Muscular Dystrophy 31 Cystic Fibrosis 31 Charcot-Marie- Tooth Disease 31 Nucleotide Repeat Disorders 32 Susceptibility Versus Causative Genes 32 Summary 34 References 34 3 Determining the Genetic Component of a Disease 36 Allison Ashley Koch and Evadnie Rampersaud Introduction 36 Study Design 37 Selecting a Study Population 37 Population-Based 38 Clinic-Based 38 Ascertainment 38 Single Affected Individual 39 Relative Pairs 40 Extended Families 40 Healthy or Unaffected Controls 41 Ascertainment Bias 42 Approaches to Determining the Genetic Component of a Disease 44 Co-segregation with Chromosomal Abnormalities and Other Genetic Disorders 44 Familial Aggregation 44 Family History Approach 44 Example of Calculating Attributable Fraction 46 Correlation Coefficients 46 Twin and Adoption Studies 47 Recurrence Risk in Relatives of Affected Individuals 48 Heritability 49 Example Using Correlation Coefficients to Calculate Heritability 50 Segregation Analysis 51 Summary 52 References 53 4 Study Design for Genetic Studies 58 Dana C. Crawford and Logan Dumitrescu Introduction 58 Selecting a Study Population 58 Family- Based Studies (Linkage) 59 Family- Based Studies (Association) 60 Studies of Unrelated Individuals (Association) 61 Cohort Studies 61 Cross- Sectional Studies 66 Case– Control Studies 66 Other Study Designs 68 Biobanks 69 Other Biobanks 71 Biospecimens for Biobanks 72 Summary 73 References 74 5 Responsible Conduct of Research in Genetic Studies 79 Susan Estabrooks Hahn, Adam Buchanan, Chantelle Wolpert,and Susan H. Blanton Introduction 79 Research Regulations and Genetics Research 80 Addressing Pertinent ELSI in Genetic Research 83 Genetic Discrimination 83 Privacy and Confidentiality 84 Certificate of Confidentiality 85 Coding Data and Samples 85 Secondary Subjects 86 Future Use of Samples/Data Sharing 87 Handling of Research Results 88 CLIA Regulations: Separation of Research and Clinical Laboratories 89 Releasing Children’s Genetic Research Results 90 DNA Ownership 90 DNA Banking 90 Family Coercion 91 Practical Methods for Efficient High-Quality Genetic Research Services 91 The Investigator as the Genetic Study Coordinator 92 Time Spent 92 Recruitment 93 Support Groups and Organizations 93 Referrals from Health Care Providers 93 Research Databases and the Internet 94 Institution Databases 94 Medical Clinics 94 Recruitment by Family Members 95 Informed Consent 95 Vulnerable Populations 96 Minors 97 Persons with Cognitive Impairment 97 Data and Sample Collection 97 Sample Collection 97 Confirmation of Diagnosis 98 The Art of Field Studies 99 Referring for Additional Medical Services 99 Maintaining Contact with Participants 100 Future Considerations 100 References 100 6 Linkage Analysis 105 Susan H. Blanton Disease Gene Discovery 107 Ability to Detect Linkage 116 Real World Example of LOD Score Calculation and Interpretation 117 Disease Gene Localization 120 Multipoint Analysis 121 Effects of Misspecified Model Parameters in LOD Score Analysis 124 Impact of Incorrect Disease Allele Frequency 124 Impact of Incorrect Mode of Inheritance 125 Impact of Incorrect Disease Penetrance 125 Impact of Incorrect Marker Allele Frequency 126 Control of Scoring Errors 127 Genetic Heterogeneity 128 Practical Approach for Model-Based Linkage Analysis of Complex Traits 131 Nonparametric Linkage Analysis 133 Identity by State and Identity by Descent 134 Methods for Nonparametric Linkage Analysis 136 Tests for Linkage Using Affected Sibling Pairs (ASP) 137 Test Based on Identity by State 137 Tests Based on Identity by Descent in ASPs 138 Simple Tests 138 Tests Applicable When IBD Status Cannot Be Determined 139 Multipoint Affected Sib-Pair Methods 141 Handling Sibships with More Than 2 Affected Siblings 142 Methods Incorporating Affected Relative Pairs 142 NPL Analysis 143 Fitting Population Parameters 145 Power Analysis and Experimental Design Considerations for Qualitative Traits 147 Factors Influencing Power of Sib-pair Methods 147 The Example of Testicular Cancer 148 Examples of Sib-Pair Methods for Mapping Complex Traits 150 Mapping Quantitative Traits 151 Measuring Genetic Effects in Quantitative Traits 152 Study Design for Quantitative Trait Linkage Analysis 154 Haseman–Elston Regression 155 Variance Components Linkage Analysis 156 Nonparametric Methods 158 The Future 159 Software Available 160 References 160 7 Data Management 169 Stephen D. Turner and William S. Bush Developing a Data Organization Strategy 170 A Brief Overview of Data Normalization 170 Database Management System (DBMS) and Structured Query Language (SQL) 172 Partitioning Data by Type 173 Sequence-Level Data 174 Sample-Level Data 174 Database Implementation 175 Hardware and Software Requirements 175 Implementation and Performance Tuning 175 Interacting with the Database Directly 176 Security 177 Other Tools for Data Management and Manipulation 177 R 177 PLINK 178 SAMtools 178 Workflow Management and Cloud Computing 178 Conclusion 179 References 179 8 Linkage Disequilibrium and Association Analysis 182 Eden R. Martin and Ren-HuaChung Introduction 182 Linkage Disequilibrium 182 Measures of Allelic Association 183 Causes of Allelic Association 184 Mapping Genes Using Linkage Disequilibrium 186 Tests of Association 187 Case–Control Tests 188 Test Statistics 188 Measures of Disease Association and Impact 189 Assessing Confounding Bias 191 Family-Based Tests of Association 192 The Transmission/Disequilibrium Test 192 Tests Using Unaffected Sibling Controls 194 Tests Using Extended Pedigrees 195 Regression and Likelihood-Based Methods 196 Association Tests with Quantitative Traits 197 Analysis of Haplotype Data 197 Genome-Wide Association Studies (GWAS) 198 Special Populations 199 HapMap 200 1000 Genomes Project 200 Summary 201 References 201 9 Genome-Wide Association Studies 205 Jacob L. McCauley, Yogasudha Veturi, Shefali Setia Verma, and Marylyn D. Ritchie Introduction 205 Definition of GWAS 206 Purpose of GWAS 206 Design 206 Technologies for High-Density Genotyping 206 Discrete and Quantitative Trait Analysis 208 Case–Control, Family-Based, and Cohort Study Designs 209 Statistical Power for Association and Correction for Testing Multiple Hypotheses 211 Data Analysis 212 Quality Control on Genotyping Call Data 212 Initial Genotyping Quality Control 213 Sample-Level Quality Control 214 SNP-Level Quality Control 215 Software Programs for Quality Control 215 Population Structure 216 Imputation 219 Genetic Association Testing 220 Meta-Analysis and “Mega-Analysis” 221 Whole-Genome Regression-Based GWAS 222 Conclusion 222 References 222 10 Bioinformatics of Human Genetic Disease Studies 228 Dale J. Hedges Introduction 228 Common Threads Genome Analysis 229 A Brief Note on Study Design 229 Data Format Manipulation 229 Planning for Adequate Computational Resources 230 Storage 231 Processing and Memory 232 Networking 232 Genomics in the Cloud 232 Processing and Analysis of Genomic Data 233 Array-Based Data 233 DNA Arrays and High-Throughput Genotyping 233 Preprocessing and Initial Quality Control 234 Genotype Calling 234 Call Efficiency 235 Data Cleaning and Additional Quality Control 236 Inferring Structural Variation From SNP-based Array Data 236 A Note on Statistical Analysis and Interpretation of Results 236 Array-Based Analysis of Gene Expression 237 Batch Effects and Data Normalization 237 Differential Expression 238 Classification and Clustering Methods 239 Visualization of Expression Data 240 Pathway and Network Analyses 240 Direct Counting and Other Expression Assay Procedures 241 Additional Uses for Oligonucleotide Arrays 242 High-Throughput Sequencing Methods for Genomics 243 Introduction 243 High-Throughput Sequencing for Genotype Inference 244 Expression Analysis from High-Throughput Sequencing Data – RNA-Seq 252 ChIP-Seq and Methylation-based Sequences 255 Bioinformatics Resources 256 Annotation of Genomic Data 257 Genome Browsers as Versatile Tools 258 Bioinformatics Frameworks and Workflows 259 Crowdsourcing and Troubleshooting 260 Data Sharing 260 References 261 11 Complex Genetic Interactions/Data Mining/Dimensionality Reduction 265 William S. Bush and Stephen D. Turner Human Diseases Are Complex 265 Complexity of Biological Systems 266 Genetic Heterogeneity 267 Statistical and Mathematical Concepts of Complex Genetic Models 268 Analytic Approaches to the Detection of Complex Interactions 270 Linkage Analysis/Genomic Sharing 270 Association Analysis 270 Genome‐Wide Association Analysis 272 Conclusion 273 References 273 12 Sample Size, Power, and Data Simulation 278 Sarah A. Pendergrass and Marylyn D. Ritchie Introduction 278 Sample Size and Power 279 Power Calculations and Simulation 282 Power Studies for Association Analysis 282 Software for Calculating Power for Association Studies, Family- or Population-Based 283 PGA: Power for Genetic Association Analyses 283 Fine-Mapping Power Calculator 284 Quanto 284 PAWE: Power for Association with Errors 284 PAWE-3D 284 GPC: Genetic Power Calculator 284 CaTS 284 INPower 284 Software for Calculating Power for Transmission Disequilibrium Testing (TDT) and Affected Sib-Pair Testing (ASP) 284 GPC: Genetic Power Calculator 284 TDT-PC: Transmission Disequilibrium Test Power Calculator 284 TDTASP 285 TDTPOWER 285 ASP/ASPSHARE 285 Simulation Software for Association Study Power Assessment 285 Backward and Forward Model Simulations 285 Coalescent Model Simulation – Short Genetic Sequences 286 Larger Coalescent Simulated Models 286 Forward Model Simulations – Short Genetic Sequences 286 Forward Model Simulations – Large Genetic Sequences 286 Resampling Simulation Tools 287 Software for Simulation of Phenotypic Data 287 Power Simulations for Linkage Analysis 288 Definitions for Power Assessments for Linkage Analysis 288 Computer Simulation Methods for Linkage Analysis of Mendelian Disease 289 SIMLINK 289 SLINK: Simulation Program for Linkage Analysis 289 SUP: Slink Utility Program 290 ALLEGRO 290 MERLIN: Multipoint Engine for Rapid Likelihood Inference 290 SimPED 290 Power Studies for Linkage Analysis – Complex Disease 290 Inclusion of Unaffected Siblings 291 Affected Relative Pairs of Other Types 291 Other Considerations 291 Genomic Screening Strategies: One-Stage versus Two-Stage Designs 291 Software for Designing Linkage Analysis Studies of Complex Disease 292 SIMLA 292 Quantitative Traits 292 Extreme Discordant Pairs 292 Sampling Consideration for the Variance Component Method 293 Software for Designing Linkage Analysis Studies for Quantitative Traits 294 SOLAR: Sequential Oligogenic Linkage Analysis Routines 294 MERLIN: Multipoint Engine for Rapid Likelihood Inference 294 SimuPOP 294 Summary 294 References 294 Index 298

Read more less

Book SynopsisNeurodevelopmental disorders arise from disturbances to various processes of brain development, which can manifest in diverse ways. They encompass many rare genetic syndromes as well as common, heritable conditions such as intellectual disability, autism, ADHD, schizophrenia and many types of epilepsy.Table of ContentsList of Contributors vii ForewordKevin J. Mitchell ix 1 The Genetic Architecture of Neurodevelopmental Disorders 1Kevin J. Mitchell 2 Overlapping Etiology of Neurodevelopmental Disorders 29Eric Kelleher and Aiden Corvin 3 The Mutational Spectrum of Neurodevelopmental Disorders 49Nancy D. Merner, Patrick A. Dion, and Guy A. Rouleau 4 The Role of Genetic Interactions in Neurodevelopmental Disorders 69Jason H. Moore and Kevin J. Mitchell 5 Developmental Instability, Mutation Load, and Neurodevelopmental Disorders 81Ronald A. Yeo and Steven W. Gangestad 6 Environmental Factors and Gene–Environment Interactions 111John McGrath 7 The Genetics of Brain Malformations 129M. Chiara Manzini and Christopher A. Walsh 8 Disorders of Axon Guidance 155Heike Blockus and Alain Chédotal 9 Synaptic Disorders 195Catalina Betancur and Kevin J. Mitchell 10 Human Stem Cell Models of Neurodevelopmental Disorders 239Peter Kirwan and Frederick J. Livesey 11 Animal Models for Neurodevelopmental Disorders 261Hala Harony-Nicolas and Joseph D. Buxbaum 12 Cascading Genetic and Environmental Effects on Development: Implications for Intervention 275Esha Massand and Annette Karmiloff-Smith 13 Human Genetics and Clinical Aspects of Neurodevelopmental Disorders 289Gholson J. Lyon and Jason O'Rawe 14 Progress Toward Therapies and Interventions for Neurodevelopmental Disorders 319Ayokunmi Ajetunmobi and Daniela Tropea Subject Index 345 Gene Index 353

Read more less

Book SynopsisThe Handbook of Behavioral Genetics and Phenotyping represents an integrative approach to neurobehavioural genetics; worldwide experts in their field will review all chapters. Advanced overviews of neurobehavioural characteristics will add immense value to the investigation of animal mutants and provide unique information about the genetics and behavioural understanding of animal models, under both normal and pathological conditions. Cross-species comparisons of neurobehavioural phenotypes will pave the way for an evolutionary understanding of behaviour. Moreover, while biological sciences are progressing towards a holistic approach to investigate the complexity of organisms (i.e., systems biology approach), an integrated analysis of behavioural phenotyping is still lacking. The Handbook of Behavioral Genetics and Phenotyping strengthens the cross-talk within disciplines that investigate the fundamental basis of behaviour and genetics. This will be the first volume in which traditioTable of ContentsList of Contributors xix Preface xxv 1 Genetic Screens in Neurodegeneration 1Abraham Acevedo Arozena and Silvia Corrochano Introduction 1 The Genetics of Neurodegenerative Disorders 2 Neurodegeneration Disease Models 4 Genetic Approaches to Discover New Genes Related to Neurodegeneration Using Disease Models 5 Saccharomyces cerevisiae 6 Caenorhabditis elegans 8 Drosophila melanogaster 9 Danio rerio 10 Mus musculus 11 Human Cellular Models and Post-mortem Material 14 The Future 14 Acknowledgments 15 References 15 2 Computational Epigenomics 19Mattia Pelizzola Background 19 Profiling and Analyzing the Methylation of Genomic DNA 19 Experimental Methods 20 Data Analysis 20 Array-based Methods 20 Sequencing-based Methods 20 Profiling and Analyzing Histone Marks 26 Experimental Methods 26 Data Analysis 27 Issues of Array-based Methods 27 Issues of NGS-based Methods 27 Integration with Other Omics Data 31 Chromatin States 32 Unraveling the Cross-talk Between Epigenetic Layers 33 References 33 3 Behavioral Phenotyping in Zebrafish: The First Models of Alcohol Induced Abnormalities 37Robert Gerlai Introduction 37 Alcohol Related Human Disorders: A Growing Unmet Medical Need 37 Unraveling Alcohol Related Mechanisms: The Importance of Animal Models 38 Face Validity: The First Step in Modeling a Human Disorder 39 Acute Effects of Alcohol in Zebrafish: A Range of Behavioral Responses 39 Chronic Alcohol Exposure Induced Behavioral Responses in Zebrafish 41 Effects of Embryonic Alcohol Exposure 42 Behavioral Phenotyping: Are We There Yet? 46 Assembling the Behavioral Test Battery 49 Concluding Remarks 50 References 50 4 How does Stress Affect Energy Balance? 53Maria Razzoli, Cheryl Cero, and Alessandro Bartolomucci Introduction 53 Stress 54 Energy Balance and Metabolic Disorders 55 Pro-adipogenic Stress Mediators 57 Pro-lipolytic Effect of Stress Mediators 57 How does Stress Affect Energy Balance? 57 Animal Models of Chronic Stress and their Impact on Energy Balance 58 Physical and Psychological (non-social) Chronic Stress Models 58 Mild Chronic Pain Models – Mild Tail Pinch, Foot Shock 58 Thermal Models – Cold and Heat Stress 64 Chronic Mild Stress Models: Chronic Mild Stress, Chronic Variable Stress, etc. 64 Restraint or Immobilization 65 Chronic Social Stress Models 66 Social Isolation, Individual Housing 66 Unstable Social Settings 66 Visible Burrow System 67 Intermittent Social Defeat (Resident/Intruder Procedure) 67 Chronic Psychosocial Stress, Sensory Contact, and Chronic Defeat stress 68 Stress, Recovery, and Maintenance: Insights on Adaptive and Maladaptive Effects of Stress 69 Molecular Mechanisms of Stress-Induced Negative and Positive Energy Balance 70 Serotonin (5-hydroxytryptamine, 5HT) 71 Orexin 71 Neuropeptide Y (NPY) 72 Ghrelin and Growth Hormone Secretagogue Receptor (GHSR) 72 Glucagon like Peptide 1 (GLP1) 73 Leptin 73 Amylin 74 Norepinephrine and β3-Adrenergic Receptor 74 Conclusion 74 References 75 5 Interactions of Experience-Dependent Plasticity and LTP in the Hippocampus During Associative Learning 91Agnès Gruart, Noelia Madroñal, María Teresa Jurado-Parras, and José María Delgado-García Introduction: Study of Learning and Memory Processes in Alert Behaving Mammals 91 Changes in Synaptic Strength During Learning and Memory 92 Classical Conditioning 92 Instrumental Conditioning 95 Changes in Synaptic Strength Evoked by Actual Learning can be Modified by Experimentally Evoked Long-term Potentiation 96 Other Experimental Constraints on the Study of the Physiological Basis of Learning Processes 100 Factors Modifying Synaptic Strength (Environment, Aging, and Brain Degenerative Diseases) 101 Different Genetic and Pharmacological Manipulations Able to Modify Synaptic Strength 103 Functional Relationships Between Experimentally Evoked LTP and Associative Learning Tasks 106 Future Perspectives 108 Context and Environmental Constraints 108 Other Forms of Learning and Memory Processes 109 Cortical Circuits and Functional States During Associative Learning 109 References 110 6 The Genetics of Cognition in Schizophrenia: Combining Mouse and Human Studies 115Diego Scheggia and Francesco Papaleo Background 115 Genetics of Schizophrenia 116 Cognitive (dys)functions in Schizophrenia 117 Translating Cognitive Symptoms in Animal Models 119 Executive Control 120 Performance in Schizophrenia 122 Animal Models 124 Working Memory 125 Performance in Schizophrenia 126 Animal Models 127 Control of Attention 128 Performance in Schizophrenia 130 Animal Models 130 Concluding Remarks 131 References 132 7 The Biological Basis of Economic Choice 143David Freestone and Fuat Balci Introduction 143 Translating from Animals to Humans 144 Reinforcement Learning in the Brain 145 Subjective Value 146 The Midbrain Dopamine System Updates Value 147 From Stimulus Value to Action Value 150 Model Based Learning 150 The Prefrontal Cortex Encodes Value 152 The Basal Ganglia Selects Actions 153 Optimal Decisions: Benchmarks for the Analysis of Choice Behavior 155 The Drift Diffusion Model 157 Temporal Risk Assessment 158 Timed-response Inhibition for Reward-rate Maximization 160 Timed Response Switching 163 Temporal Bisection 164 Numerical Risk Assessment 166 Rodent Version of Balloon Analog Risk Task 167 Conclusion 167 Acknowledgments 168 References 168 8 Interval-timing Protocols and Their Relevancy to the Study of Temporal Cognition and Neurobehavioral Genetics 179Bin Yin, Nicholas A. Lusk, and Warren H. Meck Introduction 179 Application of a Timing, Immersive Memory, and Emotional Regulation (Timer) Test Battery 190 Neural Basis of Interval Timing 191 What Makes a Mutant Mouse “Tick”? 193 Proposal of a TIMER Test Battery and Its Application in Reverse Genetics 199 Behavioral Test Battery Applications in Forward Genetics 202 Order of Behavioral Tasks 205 Location and Time of Behavioral Testing 205 Summary 205 References 206 Appendix I 226 Limitations of the individual-trials analysis for data obtained in the peak-interval (PI) procedure 226 9 Toolkits for Cognition: From Core Knowledge to Genes 229Giorgio Vallortigara and Orsola Rosa Salva Introduction 229 Core Knowledge: The Domestic Chick as a System Model 230 Numerical Competence 230 Physical Properties 230 Geometry of Space 232 Animate Agents 232 A Comparative Perspective on the Genetic and Evolutionary Bases of Social Behavior 236 From Social Experience to Genes 239 From Genes to Social Behavior 241 Future Directions 243 Conserved Mechanisms for Social Core Knowledge 243 Interactions Between Experience and Genomic Information 243 Neurogenetic Basis of Social Predispositions 243 Epigenetics and the Development of the Social Brain 244 Spatial Cognition, Another Promising Core-knowledge Domain 244 References 245 10 Quantitative Genetics of Behavioral Phenotypes 253Elzbieta Kostrzewa and Martien J.H. Kas Human Studies of Quantitative Traits 253 Mouse Studies of Quantitative Traits 254 Classical Inbred Mice 254 Quantitative Trait Loci (QTL) Analysis 254 Knock-out (KO) Mouse Lines 256 Use of Mice as Animal Model for Complex Human Traits 257 Comparative Genomic Approaches 257 Evolutionarily Conserved Behavioral Phenotypes 257 Physical Activity – Definitions and Methods of Phenotypic Measurement 258 Current Results of Quantitative Genetic Basis of PA in Humans 259 Current Results of Quantitative Genetic Basis of PA in Mice 260 KO Studies 260 QTL Studies 261 An Overlap of Genetic Findings Between the Species 261 Conclusions 265 References 265 11 Behavioral Phenotyping in Genetic Mouse Models of Autism Spectrum Disorders: A Translational Outlook 271Maria Luisa Scattoni, Caterina Michetti, Angela Caruso, and Laura Ricceri Introduction 271 Measuring Social behavior in ASD Mouse Models 272 Social Interaction Tests 272 Male-female 277 Female-female 278 Male-male 278 Social-approach 279 Sociability Test Phase 280 Social Novelty 280 Social Recognition 280 Repetitive Behavior 281 Motor Stereotypies 281 Restricted Interests 281 Behavioral Inflexibility 282 Behavioral Tests Targeting other ASD Symptoms 282 Anxiety 282 Epilepsy 283 Behavioral Phenotyping in ASD Mouse Pups 283 Future Directions: ASD Mouse Models as a Resource for Gene-environment Interaction Studies 284 Acknowledgments 285 References 285 12 Genetics of Human Sleep and Sleep Disorders 295Birgitte Rahbek Kornum The Mystery of Human Sleep 295 Sleep is Essential for Mammalian Life 295 The Function of Sleep 296 Extended Wakefulness Induces Sleep 296 Homeostatic and Circadian Regulation of Sleep and Wake 297 Adenosine and Sleep Homeostasis 298 Resistance to Sleep Loss is a Stable Phenotype 299 Genetic Markers of Response to Sleep Loss 299 A Unique Activity Pattern Characterizes the Sleeping Brain 300 Sleep Stages and Sleep Cycles 300 Genetics of the Human Sleep Electroencephalography 301 Normal Sleep Architecture is Lost in Fatal Familial Insomnia 303 Circadian Regulation of Sleep and Associated Disorders 304 Circadian Regulation of Sleep 304 Molecular Regulation of the Circadian Clock 305 The Central Circadian Clock is Entrained By Light 306 Circadian Rhythm Sleep Disorders 307 Advanced Sleep Phase Syndromes 307 Delayed Sleep Phase Syndromes 308 Short Sleep Times in Healthy Individuals 308 Destabilization of Sleep States and Narcolepsy 309 Normal Regulation of Sleep Architecture 309 Wakefulness is Associated with Cortical Activation 309 The Preoptic Area Contains Sleep-promoting Neurons 309 Mutual Inhibition Regulates Transitions Between Wake and Sleep 310 Regulation of REM Sleep 311 Narcolepsy, A Disorder of Wakefulness and REM Sleep 311 Narcolepsy with Cataplexy is Caused By Hypocretin Deficiency 312 Autoimmunity Toward Hypocretin Neurons 312 Genetic Evidence Supports the Autoimmune Hypothesis of Narcolepsy 313 Restless Legs Syndrome, A Developmental Sleep Disorder 314 Restless Legs Syndrome, A Mysterious Urge to Move 314 Restless Legs Syndrome and Dopamine Disturbances 315 Iron Deficiency Exacerbates RLS Symptoms 315 Genetic Studies Suggest Developmental Defects 316 Unresolved Issues and Future Perspectives 316 What is the Molecular and Neuroanatomical Basis for the Ultradian Rhythm of NREM-REM Sleep? 317 What is the Genetic Basis for Individual Variation in Complex Sleep Features such as Sleep Spindles and K-Complexes? 317 What is the Basis for the Individual Differences in Resistance to Sleep Loss? 317 Are Homeostatic and Circadian Mechanisms Genuinely Independent or Are They Intimately Linked? 318 What Controls the Molecular and Anatomical Diversity of Sleep Regulatory Networks Across Species? 318 References 319 13 The Endocannabinoid System in the Control of Behavior 323Edgar Soria-Gomez, Mathilde Metna, Luigi Bellocchio, Arnau Busquets-Garcia, and Giovanni Marsicano Introduction 323 Cannabinoid Effects and Endocannabinoid Functions 324 Role of the ECS in Memory Processes 325 Memory: General Background 325 Role of the ECS in Synaptic Plasticity 325 Memory Impairment Produced by Exogenous Cannabinoids 326 Cannabinoid Regulation of Memory: Neurobiological Mechanisms 327 Role of the ECS in Fear Processes 329 Fear: General Background 329 The ECS as an Endogenous Regulator of Fear Responses 331 Cannabinoid Regulation of Fear: Neurobiological Mechanisms 332 Implication of the ECS in Fear Coping Behaviors 333 Role of the ECS in Feeding Behavior 336 Feeding Behavior: General Background 336 The ECS as an Endogenous Regulator of Feeding Behavior 337 The ECS and Food Reward Circuits 338 The ECS in the Hypothalamic Appetite Network 338 The ECS in the Caudal Brainstem and Gastrointestinal Tract 340 Bimodal Control of Stimulated Food Intake by the ECS in the Brain 341 Paraventricular Hypothalamus Versus Ventral Striatum in Hypophagia induced by the ECS 342 The Olfactory Bulb and the Hyperphagic Action of the ECS 342 Conclusions 343 References 344 14 Epigenetics in Brain Development and Disease 357Elisabeth J. Radford, Anne C. Ferguson-Smith, and Sacri R. Ferrón Introduction 357 Epigenetics and Neurodevelopment 358 Histone Modifications 358 DNA Methylation 361 Hydroxymethylation 364 Genomic Imprinting 364 Non-coding RNAs 365 Neurodevelopmental Disorders with an Epigenetic Basis 366 Rett Syndrome 366 Coffin–Lowry Syndrome 367 Rubinstein–Taybi Syndrome 367 Alpha-thalassemia Mental Retardation Syndrome 367 Imprinted Neurodevelopmental Disorders 368 Trinucleotide Repeat Disorders 368 Fragile X Syndrome 370 Friedreich’s Ataxia 370 Myotonic Dystrophy 371 Huntington’s Disease (HD) 371 Epigenetics of Neurodegenerative Disorders 372 Parkinson´s Disease (PD) 372 Alzheimer´s Disease (AD) 373 The Impact of the Environment on the Epigenome 374 Epigenetic Therapy in Neurodevelopment 375 Untargeted Treatment 375 Targeted Epigenetic Modulation 377 Concluding Remarks 377 Acknowledgments 377 References 378 15 Impact of Postnatal Manipulations on Offspring Development in Rodents 395Diego Oddi, Alessandra Luchetti, and Francesca Romana D’Amato Introduction 395 Early Postnatal Environment in Laboratory Altricial Rodents 396 Rodents’ Responses to Postnatal Environment and Early Manipulations 397 Assessing Pups’ Responses to Postnatal Environment and Early Manipulation 397 Neonatal Ultrasonic Calls: Isolation-induced Vocalizations and Maternal Potentiation 397 Searching for Social Contact: Homing and Huddling Behaviors 398 Early-life Environment and Stress-Response 398 Separation from the Mother 399 Mother’s Stress 400 The Cross-fostering Paradigm 401 Repeated Cross-fostering as a Model of Early Maternal Environment Instability 403 Environmental Enrichment 405 Conclusions 406 References 407 16 Exploring the Roles of Genetics and the Epigenetic Mechanism DNA Methylation in Honey Bee (Apis Mellifera) Behavior 417Christina M. Burden and Jonathan E. Bobek Introduction 417 Genetics of Adult Honey Bee Biology and Behavior 418 Nurse to Forager Transition 418 Forager Preference 420 Techniques for Investigating the Genetic Bases of Behavior 420 QTL Mapping 421 RNA Techniques 421 Microarrays 421 RNA Sequencing 422 Experimentally Modulating the Genes Correlated with Specific Behaviors to Test Causality 422 DNA Methylation and Honey Bee Behavior 423 Honey Bee DNA Methylation Machinery and Genome-Wide Patterns 423 DNA Methylation and Task Specialization 424 DNA Methylation and Memory Consolidation 425 Techniques for Detecting and Assaying DNA Methylation 426 The Technological Bases for Most DNA Methylation Assays 426 Methylation-specific Restriction Endonucleases 426 Protein-mediated Precipitation of Methylated DNA 428 Bisulfite Conversion 428 Assaying Single CpGs, Short Sequences, and Target Regions 429 Analyzing Genome-wide DNA Methylation Patterns: Microarray-based Methodologies 431 Analyzing Genome-wide DNA Methylation Patterns: Sequencing-based Methodologies 432 Techniques for Manipulating DNA Methylation 434 Pharmacological Manipulation of DNA Methylation 434 RNA Interference as a DNMT Blockade 434 Concluding Remarks and Future Perspectives 435 References 436 17 Genetics and Neuroepigenetics of Sleep 443Glenda Lassi and Federico Tinarelli Defining Sleep 443 Sleep is Genetically Determined 445 EEG and Heritable Traits 445 Sleep Disorders and Genes 446 Sleep and Gene Expression 447 Epigenetics 448 DNA Methylation 450 Posttranslational Modifications (PTMs) 450 RNA interference 452 Neuroepigenetics 453 Two Neurodevelopmental Disorders with Opposing Imprinting Profiles and Opposing Sleep Phenotypes 453 Neuroepigenetics of Sleep 454 Fruit Fly 454 Rodent Models 454 Human Beings 456 Sleep and Parent-of-origin Effects 458 Conclusions 460 References 460 18 Behavioral Phenotyping Using Optogenetic Technology 469Stephen Glasgow, Carolina Gutierrez Herrera, and Antoine Adamantidis Introduction 469 Microbial Opsins 470 Fast Excitation Using Channelrhodopsin-2 and Its Variants 470 Fast Optical Silencing 474 Alternative strategies for cell-type specific modulation of neural activity 476 Targeting systems 476 Light Delivery in the Animal Brain 478 Recording Light-evoked Neuronal Activity 479 Behavioral Phenotyping 479 In-vivo Optogenetics: Defining Circuits 480 Perspectives 484 Acknowledgments 484 References 484 19 Phenotyping Sleep: Beyond EEG 489Sibah Hasan, Russell G. Foster, and Stuart N. Peirson Sleep Research 489 Phenotyping Sleep in Humans 490 Introduction 490 Actigraphy 490 Cardiorespiratory Signals 491 EEG 492 Phenotyping Sleep in Animal Models 494 Introduction 494 EEG 494 Introduction 494 Tethered EEG 496 Telemetered EEG 496 NeuroLogger EEG 498 Beyond EEG 498 Infrared Beam Break 499 Movement Based on Implanted Magnets 499 Piezo-electric Sensors 499 Video Tracking 500 Future Perspectives 501 Acknowledgements 502 References 502 20 A Cognitive Neurogenetics Screening System with a Data-Analysis Toolbox 507C.R. Gallistel, Fuat Balci, David Freestone, Aaron Kheifets, and Adam King Introduction 507 Mechanisms, Not Procedures 508 Functional Specificity 508 No Group Averages 509 Physiologically Meaningful Measures 509 Importance of Large-scale Screening and Minimal Handling 511 Utilizable Archived Data with Intact Data Trails 511 The System 512 The Toolbox 513 Core Commands 516 Powerful Graphics Commands 517 Results 518 Summary 523 References 524 21 Mapping the Connectional Architecture of the Rodent Brain with fMRI 527Adam J. Schwarz and Alessandro Gozzi Introduction 527 MRI Mapping of Functional Connectivity in the Rodent Brain 528 Networks of Functional Covariance 528 Connectivity of Neurotransmitter Systems 529 The Dopaminergic System 529 The Serotonergic System 531 Resting State BOLD fMRI 532 Connectivity Networks of the Rodent Brain 533 Do Rodent Brains have a Default Mode Network? 536 Use of Anesthesia and Other Methodological Considerations 539 Transgenic Models: Genetic Manipulation of Functional Connectivity Patterns 541 Future Perspectives 543 References 545 22 Cutting Edge Approaches for the Identification and the Functional Investigation of miRNAs in Brain Science 553Emanuela de Luca, Federica Marinaro, Francesco Niola, and Davide De Pietri Tonelli Introduction 553 History 553 Biology and Functions in the Brain 553 Identification of Novel MicroRNAs in the Brain 555 miRNA Extraction and Purification 556 miRNA Cloning 556 Computational Identification of Novel miRNAs 557 RNA Sequencing (RNA-Seq) 558 miRNA expression analysis in the brain 559 miRNA profiling 559 Analysis of miRNA Expression in Tissue 559 Target Identification 560 Computational Identification of Targets 561 Proteomics 561 RISC-associated miRNA Targets 562 RNomics 563 miRNA Manipulation/Target Validation 565 miRNA Inhibition 565 miRNA Over-expression 566 Target Validation 567 New Frontiers in Small RNA-based Technologies to Cure Nervous System Deficits 567 Use of miRNAs in Gene Therapy 567 Use of miRNAs in Gene Therapy in the Brain Requires Improved Delivery Strategies 571 Conclusion and Perspectives 572 Are Circulating miRNAs Novel Biomarkers for Brain Diseases? 572 Use of miRNAs in Cell Reprogramming Technology 573 Are miRNAs Just the “Tip of the Iceberg”? Emerging Classes of Noncoding RNAs and Novel Scenarios 574 Acknowledgments 575 Competing Financial Interests 575 References 575 Index 585

Read more less

Book SynopsisThe analysis and interpretation of data is fundamental to the subject of genetics and forms a compulsory part of the undergraduate genetics curriculum.Table of ContentsPreface ix Acknowledgements xi How to Use this Book xiii Section 1: Introductory 1.1 Grandma’s Secret 3 1.2 Tiger! Tiger! 7 1.3 Anticipation 13 1.4 Budgie Hell 17 1.5 Friends Reunited 21 1.6 The Footballer, his Wife, their Kids and her Lover 25 1.7 Give Peas a Chance 29 1.8 Noah’s ARC 35 1.9 The Mysterious Disappearance of Midnight 39 1.10 RANCID 45 Section 2: Intermediate 2.1 Otto’s Finger 51 2.2 The Mystery of Muckle Morag 57 2.3 Drosophila hogwashii 63 2.4 The Curse of Lilyrot 69 2.5 Strawberry Fields Forever 75 2.6 The Mystery of Trypton Fell 81 2.7 Sir Henry’s Enormous Chest 89 2.8 Pandemonium 93 2.9 My Imperfect Cousin 101 2.10 The Curse of the WERE Rabbits 107 Section 3: Advanced 3.1 The Legend of Neptune’s Cutlass 117 3.2 The Devil’s Pumpkin 129 3.3 Gravity 141 3.4 Kate and William, a Love Story 151 3.5 The Titanians 163 3.6 Once Bitten, Twice Shy 175 3.7 Red‐Crested Dragons of Mythological Island 185 3.8 I Scream! 197 3.9 The Nuns of Gaborone 209 3.10 Poissons Sans Yeux 221 Answers 233 List of Figures 361

Read more less

Book SynopsisLearn to implement effective control measures for mutagenic impurities in pharmaceutical development InMutagenic Impurities: Strategies for Identification and Control,distinguished chemist Andrew Teasdale deliversa thorough examinationof mutagenic impurities and their impact on the pharmaceutical industry. The book incorporates the adoption of the ICH M7 guideline and focuses on mutagenic impurities from both a toxicological and analytical perspective. The editor has created a primary reference for any professional or studentstudying or working with mutagenic impurities and offers readers a definitive narrative of applicable guidelines and practical, tested solutions. It demonstrates the development of effective control measures, including chapters onthe purge tool for risk assessment. The book incorporates a discussion of N-Nitrosamines which was arguably the largestmutagenic impurityissue ever faced by the pharmaceutical industry, resulting in thTable of ContentsList of Contributors xix Preface xxi Section 1 The Development of Regulatory Guidelines for Mutagenic/Genotoxic Impurities – Overall Process 1 1 Historical Perspective on the Development of the EMEA Guideline and Subsequent ICH M7 Guideline 3Andrew Teasdale 1.1 Introduction 3 1.1.1 CPMP – Position Paper on the Limits of Genotoxic Impurities –2002 4 1.1.1.1 Scope/Introduction 4 1.1.1.2 Toxicological Background 4 1.1.1.3 Pharmaceutical (Quality) Assessment 4 1.1.1.4 Toxicological Assessment 4 1.1.2 Guideline on the Limits of Genotoxic Impurities – Draft June 2004 5 1.1.3 PhRMA (Mueller) White Paper 6 1.1.4 Finalized EMA Guideline on the Limits of Genotoxic Impurities – June 2006 8 1.1.4.1 Issues Associated with Implementation 9 1.1.4.2 Control Expectations for Excipients 11 1.1.4.3 Control Expectations for Natural/Herbal Products 12 1.1.4.4 Identification of Potential Impurities 12 1.1.4.5 The Principle of Avoidance 12 1.1.4.6 The ALARP Principle 14 1.1.4.7 Overall 14 1.1.5 SWP Q&A Document 14 1.1.5.1 The Application of the Guideline in the Investigational Phase and Acceptable Limits for GIs Where Applied to Studies of Limited Duration 14 1.1.5.2 Application of the Guideline to Existing Products 15 1.1.5.3 Avoidance and ALARP 17 1.1.5.4 ICH Identification Threshold and its Relation to MI Assessment 17 1.1.6 FDA Draft Guideline 17 1.1.7 Other Relevant Guidance 17 1.1.7.1 Excipients 18 1.1.8 Herbals 18 1.1.9 ICH S9 18 1.1.10 Conclusions 19 References 19 2 ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 21Andrew Teasdale and Raphael Nudelman 2.1 Introduction 21 2.2 ICH M7 22 2.2.1 Introduction 22 2.2.2 Scope 22 2.2.2.1 Established Products 22 2.2.2.2 Anticancer Treatments 23 2.2.2.3 Nature of Therapeutic Agent/Excipients 23 2.2.3 General Principles 24 2.2.4 Considerations for Marketed Products 25 2.2.4.1 Post-approval Changes to Drug Substance, Chemistry, and Manufacturing Controls 26 2.2.4.2 Post-approval Changes to Drug Product Chemistry, Manufacturing, and Controls 26 2.2.4.3 Changes to the Clinical Use of Drug Products 26 2.2.5 Other Considerations for Marketed Products 27 2.2.6 Drug Substance and Drug Product Impurity Assessment 27 2.2.6.1 Synthetic Impurities 28 2.2.6.2 Degradation Products 28 2.2.7 Hazard Assessment 29 2.2.8 Risk Characterization 32 2.2.8.1 Acceptable Intakes Based on Compound-specific Risk Assessments 32 2.2.8.2 Acceptable Intakes for Class 2 and Class 3 Compounds 33 2.2.8.3 Multiple Impurities 34 2.2.8.4 Exceptions and Flexibility in Approaches 35 2.2.9 Control Strategy 35 2.2.9.1 Considerations for Control Approaches 37 2.2.9.2 Considerations for Periodic Testing 37 2.2.9.3 Control of Degradation Products 38 2.2.10 Lifecycle Management 38 2.2.11 Documentation 38 2.2.11.1 Clinical Trail Applications 38 2.2.11.2 Common Technical Document (Marketing Application) 39 2.2.12 Other Aspects 39 2.2.12.1 Relationship Between ICH M7 and ICH Q3A 39 2.3 Conclusions 40 2.4 Commentary on ICH M7 Questions and Answers 40 2.4.1 Section 1 – Introduction 41 2.4.1.1 Question 1.1 41 2.4.1.2 Question 1.2 42 2.4.1.3 Question 1.3 42 2.4.1.4 Question 1.4 42 2.4.2 Section 2 – Scope 43 2.4.2.1 Question 2.1 43 2.4.3 Section 3 – General Principles 43 2.4.3.1 Question 3.1 44 2.4.3.2 Question 3.2 44 2.4.4 Section 4 – Considerations for Marketed Products 44 2.4.4.1 Question 4.1 45 2.4.5 Section 5 – Drug Substance and Drug Product Impurity Assessment 45 2.4.6 Section 6 – Hazard Assessment Elements 45 2.4.6.1 Question 6.1 45 2.4.6.2 Question 6.2 46 2.4.6.3 Question 6.3 47 2.4.6.4 Question 6.4 48 2.4.7 Section 7 – Risk Characterization 48 2.4.7.1 Question 7.1 48 2.4.7.2 Question 7.2 49 2.4.7.3 Question 7.3 49 2.4.7.4 Question 7.4 50 2.4.7.5 Question 7.5 51 2.4.8 Section 9 – Documentation 53 References 55 3 Control Strategies for Mutagenic Impurities 57Andrew Teasdale, Michael Burns, and Michael Urquhart 3.1 Introduction 57 3.2 Assessment Process 58 3.2.1 General 58 3.2.2 Step 1 – Evaluation of Drug Substance and Drug Product Processes for Sources of Potentially Mutagenic Impurities 60 3.2.3 Step 2 – Structural Assessment 61 3.2.4 Step 3 – Classification 61 3.2.5 Step 4 – Assessment of Risk of Potential Carryover of Impurities 63 3.2.6 Overall Quantification of Risk 63 3.2.6.1 Predicted Purge Factor 64 3.2.6.2 Required Purge Factor 65 3.2.6.3 Purge Ratio 66 3.2.6.4 High Predicted Purge 67 3.2.6.5 Moderate Predicted Purge 67 3.2.6.6 Low Predicted Purge 67 3.2.6.7 ICH M7 Control Option 1, 2, or 3 67 3.2.6.8 Step 5 – Further Evaluation 67 3.2.6.9 Safety Testing 67 3.2.7 Quantification of Level Present 68 3.3 Step 6 – Overall Risk Assessment 69 3.4 Further Evaluation of Risk – Purge (Spiking) Studies 70 3.5 Conclusion 70 3.6 Case Studies 71 3.6.1 Case Study 1 – GW641597X 71 3.6.1.1 Ethyl Bromoisobutyrate 2 73 3.6.1.2 Hydroxylamine 74 3.6.1.3 Alkyl Chloride 8 75 3.6.1.4 Additional Evidence for the Purging of Ethyl Bromoisobutyrate and Alkyl Chloride 8 76 3.6.2 Proposed ICH M7-aligned Potential Mutagenic Control Regulatory Discussion 78 3.6.3 Case Study 2 – Candesartan 78 References 84 Section 2 In Silico Assessment of Mutagenicity 87 4 Use of Structure–Activity Relationship (SAR) Evaluation as a Critical Tool in the Evaluation of the Genotoxic Potential of Impurities 89Catrin Hasselgren and Glenn Myatt 4.1 Introduction 89 4.2 (Q)SAR Assessment 90 4.2.1 Looking-up Experimental Data 90 4.2.2 (Q)SAR Methodologies 91 4.2.2.1 Overview 91 4.2.2.2 OECD Validation Principles 91 4.2.3 Expert Rule-Based Methodology 92 4.2.4 Statistical-Based Methodology 95 4.2.5 Applying (Q)SAR Models 97 4.2.6 Expert Review 98 4.2.6.1 Overview 98 4.2.6.2 Refuting a Statistical-Based Prediction 100 4.2.6.3 Mechanistic Assessment 101 4.2.6.4 Assessing Lack of Chemical Reactivity 101 4.2.7 Class Assignment 103 4.2.7.1 Overview 103 4.2.8 Documentation 109 4.3 Discussion 109 4.4 Conclusions 110 Acknowledgments 111 References 111 5 Evolution of Quantitative Structure–Activity Relationships ((Q)SAR) for Mutagenicity 115James Harvey and David Elder 5.1 Introduction 115 5.2 Pre ICH M7 Guideline 116 5.3 Post ICH M7 117 5.3.1 Evolution of (Q)SAR Platforms 117 5.3.2 Robust Negative In Silico (Q)SAR Predictions 118 5.3.3 Development of Composite (Q)SAR Models 119 5.3.4 Expansion of Training Data Sets to Enhance the Predictive Power of (Q)SAR Tools 120 5.3.5 Focused Data Sharing Initiatives on Specific Chemical Classes 120 5.3.5.1 Understanding In Vitro Mechanisms Leading to Mutagenicity 121 5.3.5.2 Shared Data, Shared Progress 122 5.3.6 Novel Data Mining Approaches 125 5.3.6.1 Case Study: Primary Aromatic Amines (PAAs) 125 5.3.6.2 Case Study: Aromatic N-oxides 125 5.4 Expert Knowledge 127 5.5 Future Direction 129 References 131 Section 3 Toxicological Perspective on Mutagenic Impurities 137 6 Toxicity Testing to Understand the Mutagenicity of Pharmaceutical Impurities 139Andrew Teasdale, John Nicolette, Joel P. Bercu, James Harvey, Stephen Dertinger, Michael O’Donovan, and Christine Mee 6.1 Introduction 139 6.2 In Vitro Genotoxicity Tests 141 6.2.1 Background 141 6.2.2 Bacterial Reverse Mutation or “Ames” Test 142 6.2.3 Modifications to the Standard Ames Test 145 6.2.3.1 Six-well Ames Assay 146 6.2.4 Test Strategy 146 6.3 In Vivo Mutation Assays 148 6.3.1 In Vivo Pig-a Gene Mutation Assay 148 6.3.2 Rodent Micronucleus Test 152 6.3.3 Rodent “Comet” Assay 155 6.3.4 Transgenic Rodent (TGR) Mutation Assay 155 6.4 Conclusions 158 Glossary 159 References 160 7 Compound-and Class-Specific Limits for Common Impurities in Pharmaceuticals 165Joel P. Bercu, Melisa J. Masuda-Herrera, Alejandra Trejo-Martin, David J. Snodin, Kevin P. Cross, George E. Johnson, James Harvey, Robert S. Foster, David J. Ponting, and Richard V. Williams 7.1 Introduction 165 7.2 Monograph Development 167 7.2.1 Exposure to the General Population 167 7.2.2 Mutagenicity/Genotoxicity 170 7.2.3 Noncarcinogenic Effects 170 7.2.4 Carcinogenic Effects 170 7.2.5 Mode of Action (MOA) and Assessment of Human Relevance 171 7.2.6 Toxicokinetics 171 7.2.7 Regulatory/Published Limits 171 7.3 Derivation of the Compound-specific Limit 171 7.3.1 PoD Selection 172 7.3.2 Limited Data Sets 172 7.3.3 PDE Development 172 7.3.4 AI Development 172 7.3.5 Class-specific Limit 173 7.3.6 Less than Lifetime (LTL) AIs 173 7.4 Examples of Published Compound-specific Limits 173 7.4.1 Mutagenic Carcinogens 173 7.4.2 Nonmutagenic Carcinogens 176 7.4.3 Mutagenic Noncarcinogens 176 7.4.4 Nonmutagenic Compounds 176 7.4.5 Mutagenic In vitro but not In vivo 176 7.4.6 Route of Administration-specific Limits 177 7.5 Class-specific Limits 177 7.5.1 Alkyl Chlorides 177 7.5.2 Alkyl Bromides 178 7.5.3 N-Nitrosamines 178 7.5.3.1 Regulatory Limits for N-Nitrosamines 178 7.5.3.2 Additional Proposed Limits for N-Nitrosamines 180 7.5.3.3 N-Nitrosamine Exposure in the General Population 181 7.5.3.4 Developing a Class-specific Limit for N-Nitrosamines 182 7.5.4 Arylboronic Acids and Esters 193 7.6 EMS Case Study and Updated Toxicity Analysis 196 7.6.1 Potential for Human Exposure 196 7.6.2 Mutagenicity/Genotoxicity 196 7.6.3 Noncarcinogenic Effects 198 7.6.4 Carcinogenicity 199 7.6.5 Regulatory and/or Published Limits 199 7.6.6 Permitted Daily Exposure 199 7.7 Extractables and Leachables 202 7.8 Lhasa AI/PDE Database for Impurities 203 7.9 Conclusions and Future Directions 203 Acknowledgments 204 References 204 8 Genotoxic Threshold Mechanisms and Points of Departure 213George E. Johnson, Shareen H. Doak, Gareth J.S. Jenkins, and Adam D. Thomas 8.1 Introduction to Genotoxic Dose Responses 213 8.1.1 The Linear Default Position for Genotoxic Carcinogens 213 8.1.2 Theoretical Evidence for Rejecting the Linear Approach 214 8.1.3 In Vitro Experimental Evidence for Threshold Mechanism 215 8.1.4 In Vivo Evidence for Genotoxic Thresholds 218 8.2 Threshold Mechanisms 221 8.2.1 Statistical Assessment of Dose Response Data Sets 224 8.2.2 Extrapolation from One Chemical to Another 224 8.2.3 Extrapolation of Threshold Mechanisms and PoDs to Populations 225 8.3 Conclusions 227 References 227 Section 4 Quality Perspective on Genotoxic Impurities 233 9 Mutagenic Impurities – Assessment of Fate and Control Options 235Michael W. Urquhart, Andrew Teasdale, and Michael Burns 9.1 Introduction/Background 235 9.2 Reactivity 236 9.2.1 Reactivity Classification 238 9.3 Solubility – Isolated Stages 238 9.4 Recrystallization 239 9.4.1 Solubility – Liquid/Liquid Partitioning 239 9.5 Volatility 241 9.6 Chromatography 241 9.7 Other Techniques 242 9.7.1 Activated Charcoal 242 9.7.2 Scavenger Resins 242 9.8 Overall Quantification of Risk 243 9.9 Alignment to ICH M7 – Control Options 244 9.10 Control Option Selection 247 9.10.1 Predicted Purge Factor 248 9.10.2 Required Purge Factor 249 9.10.3 Purge Ratio 249 9.10.4 High Predicted Purge 250 9.10.5 Moderate Predicted Purge 250 9.10.6 Low Predicted Purge 250 9.10.7 ICH M7 Control Option 1, 2, or 3 251 9.10.8 Representative Data to be Supplied in Regulatory Submission Under an ICH M7 Control Strategy 251 9.10.9 Summary of PMI Purging Across the Synthetic Route 251 9.10.10 Details of Individual Impurity Purging Through the Subsequent Downstream Chemistry 253 9.10.11 Development of a Knowledge Base Expert In Silico System 254 9.10.12 Experimental Work to Assess Reactivity 257 9.11 Utilizing Mirabilis for a Purge Calculation 259 9.11.1 Utility of In Silico Predictions 260 9.11.1.1 Case Study – Camicinal [38] 260 References 266 10 N-Nitrosamines 269Andrew Teasdale, Justin Moser, J. Gair Ford, and Jason Creasey 10.1 Background 269 10.2 Generation of N-Nitrosamines 270 10.3 Article 31 273 10.4 Further Issues – Cross Contamination and Ranitidine 275 10.4.1 Article 5(3) and Associated Q&A Document 276 10.5 How to Assess the Risk Posed in Pharmaceuticals 278 10.5.1 Drug Substance 278 10.5.1.1 Where do Nitrites Come Within Drug Substance Come From? 278 10.5.1.2 What Other Sources Are There? 278 10.5.1.3 Other Factors Associated with Drug Substance Synthesis 280 10.5.2 Process to Assess Drug Substance-Related Risk 280 10.5.3 Drug Product-Related Risk 282 10.5.3.1 Related Risks of Contamination and Formation in Drug Products 282 10.5.4 Container Closure Systems 289 10.5.5 Elastomeric Components 291 10.5.6 Nitrosamine Impurities in Biologics 293 10.5.6.1 Active Substance 293 10.5.6.2 The Water Used in Formulation Is Depleted in Nitrosating Agents 295 10.5.6.3 Bioconjugated or Chemically Modified Products 295 10.5.6.4 Excipients 296 10.6 Regulatory Guidance Pursuant to N-Nitrosamines and its Implications 297 10.6.1 Article 31 Process and Outcomes 297 10.6.1.1 Article 31 Request 297 10.6.2 Sartans Lessons Learnt Report 298 10.6.2.1 Reflection on the Initial Section of the EMA Report 299 10.6.3 Article 5(3) Report 299 10.6.3.1 Quality 299 10.6.3.2 Consideration for Analytical Method Development to Identify and Quantify N-Nitrosamines in Drug Substances and Medicinal Products 300 10.6.3.3 Safety 301 10.6.3.4 Conclusions 305 10.6.4 EMA Question and Answer Document [6] 305 10.6.4.1 Further Revision of the EMA Question and Answer Document 310 10.6.5 FDA Guideline 310 10.6.5.1 Introduction and Background 310 10.6.5.2 Recommendations 310 10.6.5.3 Acceptable Intakes (section III.A) 313 10.6.5.4 Quality/Chemistry and Controls 314 10.7 Way Forward 315 Acknowledgments 316 References 317 11 Conditions Potentially Leading to the Formation of Mutagenic Impurities 321Lucie Lovelle, Andrew Teasdale, Ian Ashworth, Adrian Clarke, and Alan Steven 11.1 Problematic Reagent Combinations per Structural Alert 323 11.1.1 N-Nitroso Compounds (COC) 323 11.1.1.1 Amines and Nitrosating Agents [10] 323 11.1.1.2 Amine Derivatives and Nitrosating Agents 324 11.1.1.3 Other 324 11.1.2 Alkyl-azoxy Compounds (COC) 325 11.1.2.1 Reduction [52–54] 325 11.1.2.2 Oxidation 325 11.1.2.3 Others 325 11.1.3 Other N-O Compounds 326 11.1.3.1 Reduction of Nitro Groups 326 11.1.3.2 Oxidation of Amines and Hydroxylamines 326 11.1.4 Nitration 326 11.1.5 Other N-N Compounds [59, 60] 326 11.1.6 Aflatoxin-like Compounds [62] (COC) 327 11.1.7 Dioxin-like Compounds (Including Polychlorinated Biphenyls = PCBs) [63] 327 11.1.8 Alkyl and Acyl Halides 327 11.1.8.1 ROH + HCl → RCl + H2O 327 11.1.8.2 Ether Opening with Halides 328 11.1.9 Methyl Sulfoxides and Pummerer Rearrangement 328 11.1.10 Acyl Chlorides Formation [82] 329 11.1.11 Halogenation of Unsaturated Compounds 329 11.1.12 Ammonium Salts (Hofmann Elimination) 329 11.1.12.1 Alkyl Sulfonates [90] 329 11.1.13 Epoxides and Aziridines [95–97] 330 11.2 Miscellaneous 331 11.2.1 B and P Based Compounds 331 11.2.2 Formation of N-Methylol 331 11.2.3 Acetamide 332 11.2.4 Quinones and Quinone Derivatives 332 11.2.5 Anilines [100] 332 11.2.6 Michael Acceptors 333 11.2.7 Others 333 11.3 Mechanism and Processing Factors Affecting the Formation of N-nitrosamines 333 11.3.1 Introduction 333 11.3.2 Mechanisms of Amine Nitrosation 333 11.3.2.1 Nitrosation of Secondary Amines 333 11.3.2.2 Aqueous Nitrosation 334 11.3.2.3 Nitrosation in Organic Solvents 336 11.3.3 Nitrosation of Tertiary Amines 337 11.3.3.1 Nitrosation of Quaternary Amines 337 11.3.3.2 Nitrosation of Amine Oxides 338 11.3.4 Sources of Nitrosating Agents 338 11.3.4.1 Process Water 338 11.3.4.2 Nitric Acid 339 11.3.4.3 Atmospheric Sources 339 11.3.4.4 Excipients Used in Drug Product Manufacture 340 11.3.4.5 Nitrocellulose 340 11.3.4.6 Nitrosating Agent Scavengers 340 11.3.4.7 Removal of Nitrosamines 341 11.4 Formation, Fate, and Purge of Impurities Arising from the Hydrogenation of Nitroarenes to Anilines 341 11.4.1 Primary Reaction Mechanism 341 11.4.2 Mass and Heat Transfer Effects 342 11.4.3 Condensation Chemistry 344 11.4.4 Factors Affecting Aryl Hydroxylamine Accumulation 346 11.4.5 Aryl Hydroxylamine Control 347 11.4.5.1 Use of Cocatalysts 347 11.4.5.2 Physical Adsorption 348 11.4.5.3 Kinetic Understanding Around Formation and Consumption 349 11.4.5.4 Holistic Control of Impurity Profile 349 11.4.6 Controlling Residual Nitroarene 351 11.4.7 Specific Considerations of Alkyl Nitro Reductions 353 11.4.8 Closing Comments on Hydrogenation of Nitroarenes to Anilines 353 11.5 Mechanism and Processing Parameters Affecting the Formation of Sulfonate Esters – Summary of the PQRI Studies 353 11.5.1 Introduction 353 11.5.2 Reaction Mechanism 355 11.5.3 Experimental Results 357 11.5.3.1 Experimental Results from Study of the Ethyl Methanesulfonate (EMS) System 357 11.5.3.2 Other Methanesulfonic Acid Systems 359 11.5.3.3 Experimental Results from Study of the Isopropyl Methanesulfonate (IMS) System 360 11.5.4 Experimental Results from Study of Toluenesulfonic (Tosic) Acid Systems 361 11.5.4.1 Experimental Results from Study of the Ethyl Tosylate (ETS) System 362 11.5.4.2 Kinetic Modeling 363 11.5.4.3 Key Learnings and Their Implications for Process Design 365 11.5.4.4 Processing Rules 366 11.5.5 What About Viracept™? 366 11.5.6 What About Other Sources of Sulfonate Esters? 367 11.5.7 Potential for Ester Formation in the Solid Phase 368 11.5.8 Conclusions 369 References 369 12 Strategic Approaches to the Chromatographic Analysis of Mutagenic Impurities 381Frank David, Gerd Vanhoenacker, Koen Sandra, Pat Sandra, Tony Bristow, and Mark Harrison 12.1 Introduction 381 12.2 Method Development and Validation 384 12.3 Analytical Equipment for Mutagenic Impurity Analysis 385 12.4 Alkyl Halides and Aryl Halides 388 12.4.1 Method Selection 388 12.4.2 Typical Conditions Used for Alkyl-and Aryl Halide Analysis by SHS-GC-MS and SPME-GC-MS 390 12.4.2.1 Sample Preparation 390 12.4.2.2 GC-MS Parameters 391 12.4.3 Typical Results Obtained for Alkyl-and Aryl Halide Analysis by SHS-GC-MS and SPME-GC-MS 391 12.5 Sulfonates 393 12.5.1 Method Selection 393 12.5.2 Typical Conditions Used for Sulfonate Analysis by Derivatization SHS-GC-MS 394 12.5.2.1 Sample Preparation 395 12.5.2.2 Synthesis of Deuterated Internal Standards 395 12.5.2.3 GC-MS Parameters 395 12.5.3 Typical Results Obtained Using Derivatization – SHS – GC-MS 395 12.5.4 Confirmation Analysis by PTV-GC-MS 396 12.6 S-and N-mustards 398 12.6.1 Method Selection 398 12.6.2 Typical Analytical Conditions for the Analysis of N-mustards by Derivatization – SPME-GC-MS 399 12.6.2.1 Sample Preparation 399 12.6.3 Typical Results for N-mustards by Derivatization – SPME-GC-MS 399 12.7 Michael Reaction Acceptors 400 12.7.1 Method Selection 400 12.7.2 Typical Analytical Conditions for Michael Reaction Acceptors 400 12.7.2.1 Sample Preparation 401 12.7.2.2 Parameters for SHS-GC-MS 401 12.7.2.3 Parameters for Liquid Injection and GC-MS with Back-flush 402 12.7.3 Typical Results Obtained for Trace Analysis of Michael Reaction Acceptors 402 12.7.3.1 SHS with PTV 402 12.7.3.2 Liquid Injection GC-MS 403 12.8 Epoxides 404 12.8.1 Method Selection 404 12.8.2 Typical Analytical Conditions for the Analysis of Volatile Epoxides by SHS-GC-MS 406 12.8.2.1 Sample Preparation 406 12.8.2.2 SHS-GC-MS Parameters 406 12.8.3 Typical Results Obtained for Volatile Epoxides Using SHS-GC-MS 407 12.9 Haloalcohols 407 12.9.1 Method Selection 407 12.9.2 Analytical Conditions for Trace Analysis of Halo-alcohols by Derivatization and Liquid Injection - 2DGC-MS 409 12.9.2.1 Sample Preparation 409 12.9.2.2 2D-GC-MS Parameters 410 12.9.3 Typical Results for Analysis of Halo-alcohols by Derivatization and Liquid Injection - 2DGC-MS 410 12.10 Aziridines 411 12.10.1 Method Selection 411 12.10.2 Typical Analytical Conditions for RPLC-MS and HILIC-MS Analysis of Aziridines 412 12.10.2.1 Sample Preparation 412 12.10.2.2 RPLC-MS Method Parameters 413 12.10.2.3 HILIC-MS Method Parameters 413 12.10.3 Typical Results Obtained for Aziridine Analysis Using RPLC and HILIC 413 12.11 Arylamines and Amino Pyridines 414 12.11.1 Method Selection 414 12.11.2 Typical Analytical Conditions for Arylamines and Aminopyridines by RPLC-MSD 415 12.11.2.1 Sample Preparation 415 12.11.2.2 HPLC-MS Parameters 416 12.11.3 Typical Results for Arylamines and Aminopyridines by RPLC-MSD 417 12.12 Hydrazines and Hydroxylamine 419 12.12.1 Method Selection 419 12.12.2 Analytical Conditions for the Analysis of Hydrazines Using Derivatization and HPLC-MS 420 12.12.2.1 Sample Preparation 421 12.12.2.2 HPLC-MS Parameters 421 12.12.3 Typical Results Obtained for Hydrazines Using Derivatization LC-MS 421 12.13 Aldehydes and Ketones 423 12.13.1 Method Selection 423 12.13.2 Typical Analytical Conditions for Analysis of Aldehydes and Ketones by DNPH Derivatization, Followed by LC-MS Analysis 423 12.13.2.1 Sample Preparation 424 12.13.2.2 Derivatization Reagent Solution 425 12.13.2.3 HPLC-MS Parameters 425 12.13.3 Typical Results Obtained for Aldehyde Analysis by DNPH Derivatization – LC-MS 426 12.14 Nitrosamines 426 12.14.1 Method Selection 426 12.14.2 Sample preparation for SHS-GC-MS Analysis (according to ref [85]) 428 12.14.2.1 SHS-GC-MS Analysis [85] Sample Preparation 428 12.14.2.2 GC-MS (HRAM-MS) Conditions 428 12.14.2.3 UHPLC-MS Analysis 429 12.14.2.4 Sample Preparation for Hydrophilic Samples (e.g. Metformin) 429 12.14.2.5 Sample Preparation for Hydrophobic Matrices 430 12.14.2.6 UHPLC Conditions 430 12.14.2.7 HRAM-MS and MS/MS Conditions 430 12.14.3 Typical Results Obtained for Volatile N-nitrosamines Using SHS-GC-MS 430 12.14.4 Typical Results Obtained for N-nitrosamines Using LC-MS 431 12.15 Nontarget Analysis of PMI/MIs 434 12.16 Conclusions 435 Acknowledgements 436 References 436 13 Analysis of Mutagenic Impurities by Nuclear Magnetic Resonance (NMR) Spectroscopy 439Andrew R. Phillips and Stephen Coombes 13.1 Introduction to NMR 439 13.2 Why Is NMR an Insensitive Technique? 439 13.2.1 Nuclear Spin 439 13.2.2 Boltzmann Distribution 440 13.3 How Could NMR Be Used for Trace Analysis? 440 13.3.1 Generating an NMR Spectrum 440 13.3.2 Chemical Shift 442 13.3.3 Scalar Coupling 443 13.3.4 The Quantitative Nature of NMR 444 13.3.5 Relaxation 445 13.3.6 Summary 446 13.4 What Can Be Done to Maximize Sensitivity? 446 13.4.1 System Performance 447 13.4.1.1 Field Strength 447 13.4.2 Probe Performance 447 13.4.2.1 Probe Design 447 13.4.2.2 Probe Diameter 448 13.4.2.3 Cryogenically Cooled Probes 448 13.4.3 Substrate Concentration 449 13.4.4 Molecular Weight Ratio 451 13.4.5 Acquisition Time and Signal Averaging 451 13.4.6 Number of Protons and Linewidth 453 13.4.7 Resolution 455 13.4.8 Dynamic Range 455 13.4.8.1 Selective Excitation 458 13.4.8.2 Shaped Pulses 458 13.4.8.3 Quantification Using Selective Pulses 460 13.4.8.4 Excitation Sculpting 461 13.4.9 Limit Tests 461 13.4.9.1 Method Development 462 13.4.9.2 Validation 463 13.4.9.3 Unresolved Signals 463 13.4.9.4 Rapid Analysis 464 13.4.10 Expanded Use of MI NMR Methodology 464 13.4.11 Summary 464 13.5 Case Studies 464 13.5.1 Case Study 1 – An Aldehyde Functionalized MI 464 13.5.2 Case Study 2 – Use of 19F NMR 466 13.5.3 Case Study 3 – Epoxide and Chlorohydrin MIs 468 13.5.4 Case Study 4 – Sulfonate Esters 469 13.5.5 Case Study 5 – Limit Test for Poorly Resolved Signals 470 13.5.6 Case Study 6 – Using NMR MI Methodology for Cleaning Validation 472 13.6 Conclusion 473 References 475 14 Addressing the Complex Problem of Degradation-Derived Mutagenic Impurities in Drug Substances and Products 477Steven W. Baertschi and Andrew Teasdale 14.1 Introduction 477 14.1.1 Background 477 14.2 Working Definitions 478 14.3 Challenges Associated with the Assessment of Risk Posed by (Potentially) Mutagenic Degradation Products 479 14.4 Risk Assessment Process for Mutagenic Degradants 479 14.4.1 Stability-Related MRA Process Overview 479 14.4.2 Stress Studies 480 14.4.3 Accelerated Stability Studies 480 14.4.4 Long-term ICH Stability Studies 481 14.4.5 Deciding Which Products to Include in the MRA 481 14.4.6 In Silico Tools for the Prediction of Potential Degradation Products 482 14.5 Using Stress Testing to Select Degradation Products for Identification 482 14.5.1 Approach 1: Criteria for Structure Identification After Observation in Accelerated and Long-term Stability Studies 483 14.5.2 Approach 2: Criteria for Structure Identification Through Use of an Algorithm in Stress Testing Studies 483 14.5.3 Approach 3: Structure Identification Through Use of Kinetic Equivalence and Scaled ICH Q3B Thresholds 485 14.5.3.1 Kinetic Equivalence 485 14.5.3.2 Scaled ICH Q3B Thresholds 486 14.6 Development Timeline Considerations 487 14.6.1 Drug Discovery Stage 487 14.6.2 Preclinical to Phases 1/2 487 14.6.3 Phase 3 to New Drug Application (NDA) Regulatory Submission 488 14.6.4 Post-marketing/Line Extensions 488 14.7 Developing Control Strategies for (Potential) Mutagenic Degradation Products 488 14.7.1 Determining Relevancy of Potential Degradation Products and Developing Control Strategies for Actual Degradation Products 488 14.7.2 Accelerated Stability (40 °C/75% RH Six months) or Kinetic Equivalent 489 14.7.3 Photostability Studies 489 14.7.4 Degradation Chemistry Knowledge 490 14.8 Risk Assessment Process Illustrated 491 14.8.1 Case Study #1: Molecule A 491 14.8.2 Case Study #2: Galunisertib 492 14.8.3 Case Study #3: Naloxegol 494 14.8.4 Case Study #4: Selumetinib Side Chain 496 14.9 Significance of the Risk of Forming Mutagenic Degradation Products 498 14.9.1 Frequency of Alerting Structures in Degradation Products 498 14.10 Degradation Reactions Leading to Alerting Structures in Degradation Products 499 14.10.1 Frequency of Alerting Structures Giving Rise to Ames Positive Tests 503 14.10.2 Mutagenic Degradation Products: Overall Predicted Frequency 503 14.11 N-Nitrosamines: Special Considerations 503 14.11.1 Evaluation of Potential Formation of N-Nitrosamines in Drug Product 504 14.12 Conclusions 506 References 507 Index 513

Read more less

Book SynopsisWritten by the successful author team of Sandy Primrose and Richard Twyman, Genomics: Applications in Human Biology is a topical book showing how the new science of genomics is adding impetus to the advances in human health provided by biotechnology. Written to provide the necessary overview of the subject, covering technological developments, applications and (where necessary) the ethical implications. Divided into three sections, the first section introduces the role of biotechnology and genomics in medicine and sets out some of the technological advances that have been the basis of recent medical breakthroughs. The second section takes a closer look at how biotechnology and genomics are influencing the prevention and treatment of different categories of disease. Finally the contribution of biotechnology and genomics to the development of different types of therapy is descriTrade Review"Genomics is the more specialised...but still manages to cover an impressive array of topics relevant to human biology, including infectious disease, cancer and biopharmaceuticals. Wherever possible, the authors have gone out of their way to link technology and biological application." Paul B. Rainey, Times Higher Education Supplement, March 2004Table of ContentsChapter One: Biotechnology And Genomics In Medicine. Introduction. Recombinant DNA Technology. From Recombinant DNA To Molecular Medicine. Gene Medicine. Disease Models. The Impact Of Genomics On Medicine. The New Molecular Medicine. Outline Of This Book. Further Reading. Chapter Two: An Overview Of Genomics. Introduction. A Review Of Progress: The Human Genome Project. The Future: Functional Genomics. Mutational Genomics. Further Reading. Chapter Three: Genomics And The Challenge Of Infectious Disease. Microorganisms Causing Disease. Where Do New Diseases Come From?. Identifying The Causative Agent Of A Disease. Molecular Epidemiology. Host Resistance To Infection. Understanding Bacterial Pathogenicity. Comparative Genomics And Genome Plasticity. Combating Infectious Disease. Further Reading. Chapter Four: Analyzing And Treating Genetic Diseases. Genetic Disease In Context. Detecting Single Gene Disorders. Treating Single Gene Disorders. Finding Genes For Monogenic Diseases And Determining Gene Function. Analysis Of Polygenic Disorders. Haplotypes. The Major Histocompatibility Complex (MHC). Individual Responses To Drugs (Pharmacogenomics). Further Reading. Chapter Five: Diagnosis And Treatment Of Cancer. Introduction. The Impact Of Genomics On Cancer Research. New Methods For The Diagnosis Of Cancer. New Approaches To Cancer Therapy. Further Reading. Chapter Six: The Large Scale Production Of Biopharmaceuticals. Overview. The Generation Of Monoclonal Antibodies. The Large Scale Culture Of Microorganisms. The Large Scale Culture Of Animal Cells. Expression Systems. Downstream Processing. Using Gene Manipulation To Facilitate Downstream Processing. Of Biopharmaceuticals. The Quality Of Biopharmaceuticals. Good Manufacturing Practice. Alternative Production Systems. Further Reading. Chapter Seven: Genomics And The Development Of New Chemical Entities. Introduction. How Drugs Are Developed. High-Throughput Screening. Target Validation And Animal Models. Combinatorial Chemistry. Dynamic Combinatorial Libraries. Virtual Screening. Combinatorial Biosynthesis And Chemobiosynthesis. Drug Metabolism. Toxicogenomics. Further Reading. Chapter Eight: Gene And Cell Therapies. Introduction. Gene Therapy. Nucleic Acids As Drugs. DNA Vaccines. Disease Models. Cell Therapy. Further Reading.

Read more less

Book SynopsisPromises to remodel the way cardiovascular medicine is practised * Written and edited by two pioneers in this area * Specially selected material for the practising clinician * Must-have reference to this developing field to ensure up-to-date patient care .Trade Review"An excellent guide for developing, reviewing, or updating a keen understanding of genetics and its future in medicine. The book should find wide readership." Doodys ReviewTable of ContentsContributors. Foreword. Introduction. 1 The gene in the twenty-first century. Choong-Chin Liew, Victor J. Dzau. Part I: Cardiovascular single gene disorders. 2 Monogenic hypercholesterolemia. Ruth McPherson. 3 Hypertrophic cardiomyopathy. Ali J. Marian. 4 Dilated cardiomyopathy and other cardiomyopathies. Mitra Esfandiarei, Robert Yanagawa, Bruce M. McManus. 5 The long QT syndrome. Sabina Kupershmidt, Kamilla Kelemen, Tadashi Nakajima. Part II: Cardiovascular polygenic disorders. 6 Atherosclerosis. Päivi Pajukanta, Kiat Tsong Tan, Choong-Chin Liew. 7 Heart failure. Markus Meyer, Peter VanBuren. 8 The implications of genes on the pathogenesis, diagnosis and therapeutics of hypertension. Kiat Tsong Tan, Choong-Chin Liew. Part III: Therapies and applications. 9 Gene therapy for cardiovascular disease: inserting new genes, regulating the expression of native genes, and correcting genetic defects. Ion S. Jovin, Frank J. Giordano. 10 Stem cell therapy for cardiovascular disease. Emerson C. Perin, Guilherme V. Silva. 11 Pharmacogenetics and personalized medicine. Julie A. Johnson, Issam Zineh. 12 The potential of blood-based gene profiling for disease assessment. Steve Mohr, Choong-Chin Liew. Index. Colour plates

Read more less

Book SynopsisWith its unique combination of the latest research, expert advice, and compelling personal stories, this book gives previvors, survivors, and their family members the guidance they need to face the unique challenges of hereditary cancer.Trade ReviewA fine resource discussing the challenges of living in a high-risk body. Midwest Book Review An insightful and informative read. Nursing Times A top pick for any breast cancer collection. Midwest Book Review This book is an excellent resource for lay people trying to understand and deal with inherited breast and ovarian cancer. -- Judith Offman Journal of Family Planning and Reproductive HealthcareTable of ContentsForeword by Mark H. Greene, M.D.AcknowledgmentsIntroductionPart I: Understanding Cancer, Genetics, and Risk1. Breast and Ovarian Cancer BasicsMost Cancers Aren't HereditaryAn Introduction to Breast CancerAn Introduction to Ovarian CancerOther Hereditary Cancers2. A Peek Inside: Your Genes at WorkThe Evolution of Genetic Discovery: From Peas to BRCAYour Genetic ABCs . . . and a DMutations: Spelling Errors in Your DNA CookbookHow Mutations Lead to CancerWhat's So Special about BRCA?3. Defining RiskMaking Sense of StatisticsGetting Personal: Factors That Modify Your RiskIt's a Numbers Game4. Hereditary Cancer: What's Swimming in Your Gene Pool?Mutations from Mom or DadHidden Risk in the Family TreeHBOC and Other Hereditary Cancer SyndromesPlotting Your Genetic PedigreePart II: Assessing Your Risk5. Genetic CounselingThe Value of CounselingWhat to Expect from the ProcessWhy You Need an Expert to Unravel Your Genetic HistoryDeciding Who Should Test First6. Genetic Testing: Facing Your Hereditary HoroscopeWhich Test Is Right for You?Powerful, Yet ImperfectIssues for Survivors and Women in Treatment7. Decoding Your Test ResultsLife, Interrupted: It's PositiveGood News! You're a True NegativeWhen No Might Mean MaybeGenetic VariantsNow What? Implications for You and Your FamilyPart III: Managing Your Risk: Your DNA Doesn't Have to Be Your Destiny8. Early Detection StrategiesHigh-Risk Surveillance for Breast CancerHigh-Risk Surveillance for Ovarian CancerIs It Cancer?Screening for Other Hereditary Cancers9. ChemopreventionRisk-Reducing Medications for Breast CancerAlternatives under StudyChemoprevention for Ovarian Cancer10. Mastectomy for Risk Reduction and TreatmentReducing Cancer Risk by Removing the BreastsSkin-Sparing ProceduresTreating Breast Cancer with MastectomyWho Should Perform Your Surgery?Risks and Recovery11. Reconstruction: New Breasts after MastectomyDelaying Reconstruction to Complete Breast Cancer TreatmentLiving with a Flat ChestSaline and Silicone ImplantsOptions for Using Your Own TissueOptional Last Steps: Adding Nipples and AreolasGreat Expectations: Surgery and RecoveryChoosing the Right Surgeon12. Oophorectomy and Other Risk-Reducing Gynecologic SurgeriesOophorectomy ProceduresShould You Have a Hysterectomy Too?Oophorectomy, Mastectomy: Either, Neither, or Both?Issues for Breast Cancer Survivors13. Dealing with Menopause and Quality-of-Life IssuesSymptoms of Surgical MenopauseLong-Term Side EffectsShould You Take Hormones?Issues for Breast Cancer SurvivorsPart IV: Living with BRCA: Issues and Answers14. Managing Lifestyle ChoicesThe Three-Legged Stool: Nutrition, Weight, and Physical ActivityAlcohol: An Unwise ChoiceOther Lifestyle Risk Factors15. Sharing Information with Friends, Family, and CoworkersSharing Risk and Genetic Testing Information with FamilyIssues for Spouses, Partners, and People You DateWhat Should You Tell Employers and Coworkers?16. Young and at High RiskShould You Consider Testing Now?Diagnostic DifficultiesDealing with a Diagnosis before MenopausePlanning Your Family, Preserving Your FertilityOophorectomy in Young WomenSorting through Emotions17. How BRCA Affects MenMen Get Breast Cancer TooHigh Risk for Prostate CancerOther BRCA-Related Cancers18. Diagnosis: Hereditary CancerHow Important Is a Second Opinion?Treating Hereditary CancersMaking Breast Cancer Treatment DecisionsOvarian Cancer IssuesThe Importance of Clinical Trials19. Putting the Pieces Together to Make Difficult DecisionsStart at the Beginning: Should You Be Tested?Making Decisions to Reduce Your RiskMaking Decisions about TreatmentFrom Confused to Clear in Fifteen StepsNotesIndex

Read more less

Book SynopsisThis guide is essential for health professionals seeking more information about this underdiagnosed disease.Trade ReviewThis book is an excellent basic overview of HHT. It describes the condition, the difficulties often found in diagnosis, current and potential future treatments, as well as emotional and social effects for both patients and their families along with coping strategies. Throughout, the ability to live well with knowledge and appropriate care is emphasized.—Jeffrey Pollak, MD, Katharine Henderson, MS, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, Journal of Radiology NursingTable of ContentsAcknowledgmentsIntroductionPart I1. Diagnosis2. The Trouble with Telangiectasias3. HHT's Hidden DangersPart II4. Taking Care of Yourself5. Taking Care of Your Family6. Beyond the FamilyPart III7. Frontiers in HHT ResearchNotesGlossaryResourcesIndex

Read more less

Book SynopsisThe most comprehensive guide available on hereditary cancers, from understanding risk, prevention, and genetic counseling and testing to treatment, quality of life, and more. Up to 10 percent of cancers are caused by inherited mutations in specific genes. Finding out that you or your loved ones may be at increased risk of developing cancer because of a genetic mutation raises a lot of questions: Is cancer inevitable? Is there anything I should do differently in my life? Will my children also be at higher risk of cancer? Should I have preemptive treatments or surgery? This comprehensive guide provides answers to these questions and more. Written by three passionate patient advocates, this book is a compilation of the trusted information and support provided for more than two decades by Facing Our Risk of Cancer Empowered (FORCE), the de facto voice of the hereditary cancer community. Combining the latest scientific research with national guidelines, expert advice, and compelling patieTable of ContentsList of TablesForeword, by Matthew Boland Yurgelun, MDIntroductionPart I. Understanding Cancer and Inherited Risk1. The Link between Genetics and CancerThe Basics of GeneticsGene Wear and Tear and Repair How Cancers Develop and Grow Most Cancers Aren't Caused by Inherited Mutations2. What's Swimming in Your Gene Pool?Hidden Risk in the Family TreePlotting Your Genetic Pedigree3. Signs of Hereditary CancerThe Value of Genetic Counseling Making Decisions about Testing Insurance CoveragePrivacy and Protection4. What Your Test Results Tell YouPositive, Negative, Maybe Making Sense of StatisticsYou Have a Mutation; Now What?Part II. Inherited Gene Mutations and the Cancers They Cause5. Introducing BRCA1 and BRCA2Who Inherits a BRCA Mutation?Signs of a BRCA MutationLevels of Risk6. Lynch Syndrome: Five Genes, One Hereditary SyndromeSigns of Lynch Syndrome in FamiliesLevels of Risk7. Other Genes That Are Linked to Inherited Cancer RiskLess Known, Less Studied Genes8. Breast Cancer BasicsSigns and SymptomsWhat Affects Breast Cancer Risk?Types of Breast Cancer9. Gynecologic CancersOvarian, Fallopian Tube, and Primary Peritoneal CancersEndometrial Cancers10. Gastrointestinal CancersColorectal CancerSmall Bowel CancerPancreatic CancerStomach CancerAnal Cancer11. Genitourinary CancersProstate CancerBladder, Ureter, and Renal Pelvis Cancers12. MelanomaMelanoma of the SkinOcular MelanomaPart III. Strategies for Risk Reduction and Early Detection13. Risk Management GuidelinesGuidelines for BRCA1 or BRCA2 Gene MutationsGuidelines for Lynch Syndrome Gene MutationsGuidelines for Mutations in Other Genes14. Early Detection Strategies for High-Risk PeopleThe Vocabulary of ScreeningSurveillance for Breast CancerSurveillance for Gynecologic CancersSurveillance for Gastrointestinal CancersSurveillance for Prostate and Other Genitourinary Cancers Surveillance for MelanomaScreening for Other Hereditary Cancers15. Medications That Reduce Cancer RiskRisk-Reducing Medications for Breast CancerRisk-Reducing Medications for Gynecologic CancersRisk-Reducing Medications for Colorectal Cancers16. Surgeries That Reduce Breast Cancer RiskMastectomy ProceduresBreast Reconstruction ChoicesSide Effects, Risks, and Recovery17. Surgeries That Reduce the Risk of Gynecologic CancersSalpingo-Oophorectomy to Reduce the Risk of Ovarian CancerHysterectomy to Reduce the Risk of Endometrial Cancer18. Surgeries That Reduce the Risk of Gastrointestinal CancersTotal and Segmental Colectomy to Reduce the Risk of Colon CancerTotal Gastrectomy to Reduce the Risk of Stomach Cancer19. Factors That Affect Cancer RiskNutrition, Weight, and Physical Activity Alcohol: An Unwise ChoiceSmoking and Tobacco ProductsOther Lifestyle and Behavioral Risk FactorsPart IV. Treatment Choices for Hereditary Cancers20. Identifying Tumor Characteristics That Inform Treatment ChoicesStaging and Grading CancerTargeted Approaches to TreatmentDNA Damage Repair Genes21. Treating Breast CancerCancer Type, Subtype, and StageBiomarker TestingGenetic TestingOptions for TreatmentFollow-Up Care22. Treating Gynecologic CancersOptions for Ovarian, Fallopian Tube, and Primary Peritoneal CancersOptions for Endometrial Cancer23. Treating Gastrointestinal CancersOptions for Colorectal CancerOptions for Pancreatic CancerOptions for Gastric Cancer24. Treating Genitourinary CancersOptions for Prostate CancerOptions for Bladder, Renal Pelvis, and Ureter Cancers25. Treating Melanoma Options for Melanoma in the SkinOptions for Ocular MelanomaPart V. Living with Inherited High Risk26. Regaining Sexual Health and IntimacyBody ImageCoping with PainReduced Sexual DesireErectile DysfunctionRebuilding Intimacy27. Effects of Prevention and Treatment on FertilityPreserving Fertility in WomenPreserving Fertility in MenOther Parenting Alternatives28. Managing MenopauseSymptoms of Early MenopauseReplacement HormonesLong-Term Side Effects29. Side Effects and Other Quality-of-Life IssuesSummarizing Side Effects by TreatmentManaging Immediate Side EffectsLong-Term Effects of Prevention and TreatmentPrevivorship, Survivorship, and Follow-Up CareEnd-of-Life Issues30. Making Difficult Decisions Start at the Beginning: Should You Be Tested?Decisions about Your Cancer RiskDecisions about TreatmentPrevention and Treatment Clinical TrialsDecision-Making in 15 Steps31. You Are Not AloneCreate a Support SystemFind Emotional StrengthPursue Financial ResourcesLook to the HorizonAcknowledgmentsGlossaryNotesResourcesIndex

Read more less

Book Synopsis1 Chorionic Villus Sampling.- Early Trophoblast Development.- Historical Perspectives.- Techniques of Chorionic Villus Sampling.- Chromosomal Analysis.- Metabolic Analysis of Chorionic Villi.- DNA Analysis of Chorionic Villi.- 2 The Molecular Genetics of Hemophilia A and B in Man: Factor VIII and Factor IX Deficiency.- Hemophilia A. Factor VIII Gene.- Hemophilia B. Factor IX Gene.- X-Chromosome Mapping of Factor VIII and IX Genes.- Lessons from the Study of the Molecular Genetics of Hemophilia.- References.- 3 Cloning of the Duchenne/Becker Muscular Dystrophy Locus.- Strategies to Approach the Gene.- Detection of Deletions in DMD and BMD Patients.- Identification of the DMD Transcript.- The DMD Locus.- The DMD/BMD Protein.- Future Prospects.- References.- 4 Trisomy 21: Molecular and Cytogenetic Studies of Nondisjunction.- Scope of the Problem.- Problems to Be Addressed.- Molecular Cytogenetic Organization of Chromosome 21: Implications for Studies of Nondisjunction.- An Experimental Design to Answer the Basic Questions Related to Nondisjunction.- Overview.- References.- 5 Molecular Genetics of Human Salivary Proteins and Their Polymorphisms.- Salivary Protein Polymorphisms.- Molecular Genetic Studies.- Statherin.- Amylase Gene Family.- Cystatin Gene Family.- References.- Addendum.Table of Contents1 Chorionic Villus Sampling.- Early Trophoblast Development.- Historical Perspectives.- Techniques of Chorionic Villus Sampling.- Overview.- Transcervical Catheter Aspiration.- Transcervical Endoscopy.- Transcervical Biopsy Forceps.- Transabdominal Sampling.- Sample Processing.- Chromosomal Analysis.- Direct Karyotype Analysis.- Karyotype Analysis of Cultured Villi.- Results of Karyotype Analysis.- Metabolic Analysis of Chorionic Villi.- Overview.- Metabolic Disorders Diagnosed.- Pitfalls of Metabolic Diagnosis.- DNA Analysis of Chorionic Villi.- Overview.- DNA Disorders Diagnosed.- Pitfalls in DNA Diagnosis of Chorionic Villi.- Contraindications to Chorionic Villus Sampling.- Safety of Chorionic Villus Sampling.- Future Applications.- References.- 2 The Molecular Genetics of Hemophilia A and B in Man: Factor VIII and Factor IX Deficiency.- Hemophilia A. Factor VIII Gene.- Cloning and Characterization of Factor VIII Gene and the Deduced Protein Sequence.- Mutations in the Factor VIII Gene in Hemophilia A.- DNA Polymorphisms in the Factor VIII Gene.- Hemophilia B. Factor IX Gene.- Cloning and Characterization of Factor IX Gene.- Mutations in the Factor IX Gene in Hemophilia B.- DNA Polymorphisms in the Factor IX Gene.- X-Chromosome Mapping of Factor VIII and IX Genes.- Lessons from the Study of the Molecular Genetics of Hemophilia.- References.- 3 Cloning of the Duchenne/Becker Muscular Dystrophy Locus.- Background Information: Clinical Aspects of DMD.- Background Information: Biochemical Aspects of DMD.- Chromosomal Map Position.- Strategies to Approach the Gene.- Detection of Deletions in DMD and BMD Patients.- Identification of the DMD Transcript.- The DMD Locus.- The DMD/BMD Protein.- Future Prospects.- References.- 4 Trisomy 21: Molecular and Cytogenetic Studies of Nondisjunction.- Scope of the Problem.- Problems to Be Addressed.- Correct and Complete Ascertainment of Parental Origin of Nondisjunction.- The Maternal Age Conundrum: Is the Maternal Age Effect due to Increased Production of Abnormal Eggs or Decreased Destruction of Abnormal Embryos?.- Identification of Couples at High Risk for Trisomy 21 Offspring..- Is There a Correlation between Crossing Over and Nondisjunction on Chromosome 21?.- The Effect of the Parental Origin of Trisomy on the Phenotype of the Conceptus.- Molecular Cytogenetic Organization of Chromosome 21: Implications for Studies of Nondisjunction.- Organization of DNA Sequences on the Short Arms of the Acrocentric Chromosomes.- The Interspersed 724 Family on the Acrocentric Short Arms.- Isolation of a Large Number of Polymorphic Single-Copy DNA Probes That Span the Long Arm of Chromosome 21.- Lessons from a Pilot Study.- An Experimental Design to Answer the Basic Questions Related to Nondisjunction.- Complete Ascertainment of Parental Origin and Meiotic Stage of Nondisjunction.- The Maternal Age Conundrum: Is the Maternal Age Effect due to Increased Production of Abnormal Eggs or Decreased Destruction of Abnormal Embryos?.- Identification of Couples at High Risk for Trisomy 21 Offspring.- Is There a Correlation between Crossing Over and Nondisjunction on Chromosome 21?.- The Effect of the Parental Origin of Trisomy on the Phenotype of the Conceptus.- Overview.- References.- 5 Molecular Genetics of Human Salivary Proteins and Their Polymorphisms.- Salivary Protein Polymorphisms.- Salivary Amylase (Amy).- B12-Binding Protein (Rs).- Salivary Acid Phosphatase (s-AcP).- Genetic Polymorphisms of Proline-Rich Proteins (PRPs).- Salivary Peroxidase (SAPX).- Parotid Basic Proteins (Pb).- Other Polymorphisms in Human Saliva.- Molecular Genetic Studies.- The Proline-Rich Protein (PRP) Gene Family.- Statherin.- Amylase Gene Family.- Cystatin Gene Family.- References.- Addendum.

Read more less

Book Synopsis1 Cytogenetics of Pregnancy Wastage.- Estimation of Pregnancy Wastage.- Evaluation of the Incidence of Chromosome Abnormalities.- Types of Chromosome Abnormalities.- Animal Model for Meiotic Nondisjunction and Experimentally Induced Monosomy and Trisomy.- Conclusion.- References.- 2 Mutation in Human Populations.- Classes of Mutation.- Mutation Rate Estimates.- Some Special Problems.- Use of Mutation Rates in Genetic Counseling.- Population Kinetics of Mutation.- Assessing the Population Mutation Burden.- Mutation and Evolution.- References.- 3 Genetic Mutations Affecting Human Lipoprotein Metabolism.- General Review.- Mutations in the Pathway of Lipoprotein Metabolism.- Future Directions.- References.- 4 Giucose-6-Phosphate Dehydrogenase.- Glucose-6-Phosphate Dehydrogenase in Evolution.- The G6PD Gene in Humans.- Genetic Variability of Human G6PD.- Expression of G6PD and G6PD Deficiency.- G6PD Polymorphism and Malaria Selection.- Concluding Remarks.- References.- 5 Steroid Sulfatase Deficiency and the Genetics of the Short Arm of the Human X Chromosome.- Sulfated Steroids and their Metabolism.- Steroid Sulfatase (STS).- Steroid Sulfatase Deficiency.- Genetics of Steroid Sulfatase.- Some Genes on the Human X-chromosome Short Arm Are Not Inactivated.- Pairing and Recombination of X and Y Chromosomes.- Conclusion.- References.- Addenda.Table of Contents1 Cytogenetics of Pregnancy Wastage.- Estimation of Pregnancy Wastage.- Evaluation of the Incidence of Chromosome Abnormalities.- Spontaneous Abortions.- Induced Abortions.- Perinatal Deaths.- Types of Chromosome Abnormalities.- Autosomal Trisomies and Monosomies.- Sex Chromosome Aneuploidies.- Errors of Chromosome Haploid Sets.- Mosaicism.- Structural Anomalies.- Animal Model for Meiotic Nondisjunction and Experimentally Induced Monosomy and Trisomy.- Model for the Study of Meiotic Malsegregation and Preferential Segregation of Rb Chromosomes.- Model of Multiple Rb Heterozygosity for Production of High Rates of First Meiotic Anaphase Nondisjunction and Evaluation of Prenatal Losses.- Developmental Profiles of Monosomy and Trisomy: Principles and Mechanisms of Abnormal Development.- Perspectives for Studies in the Mouse.- Conclusion.- References.- 2 Mutation in Human Populations.- Classes of Mutation.- Classification by Phenotypic Effect.- Classification by Genomic Effect.- Number and Incidence of Human Mendelian Traits.- Mutation Rate Estimates.- Methods.- Results.- Some Special Problems.- Parental Age Effects.- Sex Differences in Mutation Rates.- Heterogeneity of Mutation Rates.- Population Monitoring.- Use of Mutation Rates in Genetic Counseling.- Population Kinetics of Mutation.- Equilibrium between Mutation and Selection.- The Rarity of Complete Recessivity.- Effects of a Change of Mutation Rate and of Environment.- The Effect of a Single Burst of Mutations.- Assessing the Population Mutation Burden.- The Mutation Load and Mutation Impact.- The Mutation Component of Genetic Disease.- Mutation and Evolution.- The Importance of Mutation Rate in Evolution.- Evolutionary Adjustment of Mutation Rates.- The Human Population.- References.- 3 Genetic Mutations Affecting Human Lipoprotein Metabolism.- General Review.- Pathway of Lipoprotein Metabolism.- Apoprotein Structure and Function.- Mutations in the Pathway of Lipoprotein Metabolism.- Mutations in LDL Receptor Pathway.- Mutations in Apoproteins.- Mutations in Enzymes Participating in Lipoprotein Catabolism.- Future Directions.- References.- 4 Giucose-6-Phosphate Dehydrogenase.- Glucose-6-Phosphate Dehydrogenase in Evolution.- Evolution of Enzyme Structure and Function.- Evolution of Genetic Variability.- Evolution of Expression.- The G6PD Gene in Humans.- Cloning of cDNA.- The Gd Gene and the X Chromosome.- Gd Mutants in Cultured Cells.- Genetic Variability of Human G6PD.- General Patterns of Variation.- Polymorphic Nondeficient Variants.- Polymorphic Deficient Variants.- Are Some G6PD Mutants Double Mutants?.- Expression of G6PD and G6PD Deficiency.- G6PD Deficiency in Erythrocytes.- G6PD and G6PD Deficiency in Nonerythroid Cells.- Acquired Changes.- G6PD Polymorphism and Malaria Selection.- Summary of Evidence.- In vitro Culture Work.- Objections.- Conclusion.- Concluding Remarks.- References.- 5 Steroid Sulfatase Deficiency and the Genetics of the Short Arm of the Human X Chromosome.- Sulfated Steroids and their Metabolism.- Cholesterol Sulfate.- DHEA Sulfate.- DHEAS and Estrogen Production.- Steroid Sulfatase (STS).- Steroid Sulfatase Deficiency.- Clinical Features of Steroid Sulfatase Deficiency.- X-linked Ichthyosis.- Testicular Abnormalities.- Steroid Metabolism in STS Deficiency.- Testicular Metabolism in STS Deficiency.- Genetics of Steroid Sulfatase.- Somatic Cell Studies.- Deletion Mapping.- STS in Other Species.- Some Genes on the Human X-chromosome Short Arm Are Not Inactivated.- STS Is Not Inactivated.- The MIC2X and MIC2Y Loci.- Inactivation and Structurally Abnormal X Chromosomes.- STS and Studies of X Inactivation.- Pairing and Recombination of X and Y Chromosomes.- Conclusion.- References.- Addenda.

Read more less

Book SynopsisThe largest section of this volume will be devoted to several important areas in human genetics: human genetic disorders which feature premature aging, the effect of human parental aging on the production of genetically abnor­ mal offspring, the genetics of human longevity, and a review of studies on aging human twins.Table of ContentsI. Genome Level.- 1 Molecular Genetics of Aging.- 1. Introduction.- 2. Mechanisms for the Inheritance of the Patterns of Senescence and Longevity.- 2.1. Explicit Inheritance.- 2.2. Implicit Inheritance.- 3. Molecular-Genetic Mechanisms of Senescence.- 3.1. Altered Molecules.- 3.1.1. Somatic Mutations.- 3.1.2. Error Catastrophe.- 3.1.3. Compensation and Repair.- 3.2. Programmed Aging.- 4. Conclusion.- References.- 2 Cytogenetics of Aging.- 1. Introduction.- 2. Alterations in Lymphocyte Chromosome Complement with Human Aging.- 3. Population Studies.- 4. Aneuploidy, Aging, and Organic Brain Disease.- 5. Effect of Genotype on Aneuploidy.- 6. Specific vs. Nonspecific Chromosome Loss.- 7. Polyploidy.- 8. Cross-Sectional vs. Longitudinal Studies.- 9. Chromosomal Alterations with Aging in Tissues Other than Lymphocytes.- 10. Effect of Experimental Conditions on Chromosome Number.- 11. In Vivo Examination of Aneuploidy.- 12. Studies of the Stability of the Chromosome Complement with in Vitro “Aging”.- 13. Chromosomal Alteration, Malignancy, and Aging.- 14. Mechanisms for the Loss of Specific Chromosomes with Aging.- 14.1. Survival of Cells Missing Specific Chromosomes.- 14.2. Selective Loss of Specific Chromosomes.- 14.3. Effect of Aging on Selection.- 15. Future Research on the Cytogenetics of Aging.- 16. Summary.- References.- 3 Aging and DNA-Repair Capability.- 1. Introduction.- 2. DNA-Repair Processes.- 2.1. Strand-Breakage Rejoining.- 2.2. Excision Repair.- 2.3. Postreplication Repair.- 2.4. Photoreactivation.- 2.5. Assay Systems for DNA Repair.- 3. Age-Related Occurrence of Unrepaired DNA Lesions.- 3.1. DNA Strand Breakage.- 3.2. DNA Cross-Linking.- 3.3. Chromosome Aberrations.- 4. DNA-Repair Capability as a Function of Age.- 4.1. In Vitro Investigations.- 4.2. In Vivo Investigations.- 5. Tissue-Specific DNA-Repair Capability.- 6. Acceleration of the Aging Process by Exposure to DNA-Damaging Agents.- 7. Human Genetic Syndromes.- 7.1. Syndromes of DNA-Repair Deficiency.- 7.2. Syndromes of Accelerated Aging.- 7.3. Conclusions.- 8. Longevity and DNA-Repair Processes.- 9. Summary and Conclusion.- References.- 4 Somatic Mutations and Aging.- 1. Introduction.- 2. Terminology of Mutagenesis.- 2.1. Concepts and Definitions.- 2.2. Mutations in Nondividing Cells.- 3. Metabolic Stability of DNA: Contrast to Turnover of Intracellular Macromolecules.- 4. Accumulation of Somatic Mutations with Aging.- 4.1. Chromosome Aberrations.- 4.2. Distinguishing Somatic Mutations from Errors.- 4.3. Base-Substitution Mutations.- 4.4. Germinal vs. Somatic Mutations.- 5. Mutagens, Carcinogens, Cancer, and Aging.- 5.1. Age-Associated Incidence of Cancer in Man and Other Mammals.- 5.2. Mutagenicity of Chemical Carcinogens.- 6. Special Genetic Mechanisms of Aging.- 7. Summary.- References.- II. Organism Level.- 5 Genetics of Aging in Lower Organisms.- 1. Introduction.- 2. Inheritance of Life Span.- 2.1. Effect of Chromosome Number on Longevity.- 2.2. Effect of Genotype on Longevity.- 2.3. Cytoplasmic Inheritance of Aging in Fungi.- 2.4. Effect of Parental Age on Longevity.- 3. Induction of Aging in Immortal Organisms.- 3.1. “Spanning” of Amoeba.- 3.2. Mutants of Neurospora.- 3.3. Autogamy-Deprived Paramecia.- 4. Summary and Conclusions.- References.- 6 Evolution of Longevity and Survival Characteristics in Mammals.- 1. Introduction.- 2. Evolutionary Gerontology: What Evolved, Aging or Longevity?.- 2.1. Allometry of Vertebrate Life Span.- 2.2. “Senescence Gene” Hypothesis of the Evolution of Aging.- 2.3. Evolution of Longevity by Means of Longevity-Assurance Genes.- 3. Evolution of Longevity in Man and the Other Mammals.- 4. Life Tables for Natural Populations.- 5. Evolutionary Change of the Parameters of the Gompertzian Survival Characteristic.- 6. Conclusion.- References.- III. Human Genetics.- 7 Human Genetic Disorders that Feature Premature Onset and Accelerated Progression of Biological Aging.- 1. Introduction.- 2. Specific Criteria of Aging.- 2.1. Physiological Markers.- 3. Premature Aging.- 3.1. General Criteria.- 3.2. A Specific Scoring System for Premature Aging.- 4. Description of Selected Disorders That Feature Premature Aging.- 4.1. Classic Progeroid Syndromes.- 4.2. Numerical Chromosome Anomalies.- 4.3. Miscellaneous Inherited Syndromes.- 5. Comparison of Premature Aging Syndromes with Normal Biological Aging.- 6. Tissue Culture Approaches to Premature Aging.- 6.1. Studies on Cell Growth.- 6.2. Defective Molecules in Prematurely Aging Cells.- 7. Significance of Biochemical Defects in Prematurely Aging Fibroblasts.- 7.1. Defects in Protein Turnover.- 7.2. Defects in RNA Turnover.- 7.3. Defects in DNA Repair.- 7.4. Defects in DNA Replication.- 8. Conclusions and Future Directions.- References.- 8 Parental-Age Effects: Increased Frequencies of Genetically Abnormal Offspring.- 1. Introduction.- 2. Maternal- vs. Paternal-Age Effects.- 3. Maternal-Age-Related Disorders.- 4. Paternal-Age-Related Disorders.- 5. Proposed Etiological Agents.- 5.1. Radiation.- 5.2. Chemicals.- 5.3. Autoimmunity.- 5.4. Infectious Agents.- 5.5. Genetic Predisposition.- 5.6. Preovulatory Overripeness.- 5.7. Postovulatory Aging.- 6. Mechanisms of Nondisjunction.- 6.1. Nucleolar Organization.- 6.2. Univalent Formation.- 6.3. Premature Centromere Division.- 7. Approaches to Studying Parental-Age Effects.- 8. Prevention by Genetic Counseling and Prenatal Diagnosis.- 9. Summary.- References.- 9 Genetics of Longevity in Man.- 1. Introduction.- 2. Evolutionary Implications.- 3. Genetics and Length of Life.- 3.1. Aging May Be Ineluctable.- 3.2. Aging May Be a Programmed Self-Destruction.- 3.3. Aging May Be an Exogenous Process.- 4. Analysis of Empirical Data.- 5. Models of Aging.- 5.1. External Models.- 5.2. Internal Models.- 5.3. Composite Models.- 5.4. Constructive Models.- 6. Studies of the Inheritance of Longevity.- 6.1. Previous Studies.- 6.2. The Baltimore Longevity Study.- 6.3. Our Extension of the Baltimore Study.- 7. Summary and Conclusion.- References.- 10 A Longitudinal Study of Aging Human Twins.- 1. Introduction: History, Methodology, and Purpose.- 2. Genetic Factors and Survival.- 3. Genetic Factors and Mental Functioning.- 3.1. Test-Battery Description and Initial Assessment.- 3.2. Longitudinal Changes in Psychological Test Performance.- 3.3. Psychological Testing and Prediction of Survival.- 3.4. Test Performance, Ability, and Education as Factors in Aging.- 4. Chromosome Change and Survival.- 5. Chromosome Change and Mental Functioning.- 6. Sex Differences and Survival.- 7. Sex Differences and Mental Functioning.- 8. Summary and Conclusions.- References.- IV. Genetic Approaches to Aging Research.- 11 Somatic Cell Genetics in the Analysis of in Vitro Senescence.- 1. Introduction.- 2. Biology of Cultured Mammalian Cells.- 2.1. Historical Background.- 2.2. The Phenomenon of in Vitro Senescence.- 2.3. Relevance of in Vitro Senescence to in Vivo Senescence.- 3. Phenotype of the Senescent Culture.- 3.1. Alterations of Proliferative Behavior with Senescence.- 3.2. Cytogenetic Alterations.- 3.3. Morphology.- 3.4. Implication for Genetic Studies.- 4. Somatic Cell Genetic Studies of in Vitro Cellular Senescence.- 4.1. Theories of the Mechanism of in Vitro Senescence.- 4.2. Scope of Somatic Cell Genetics.- 4.3. Heterokaryon Studies.- 4.4. Enucleation—Fusion Studies.- 4.5. Synkaryon Studies.- 5. Discussion.- References.- 12 Immunogenetics of Aging.- 1. Introduction.- 2. Histocompatibility Systems and Immune Responses.- 3. Immune Functional Changes with Age.- 3.1. T-Dependent Immune Functions.- 3.2. T-Independent Immune Functions.- 3.3. Autoimmunity.- 4. Genetic Influences of Immune Function in Aging.- 4.1. Influence of Sex.- 4.2. Influence of Strain or Race.- 4.3. Studies in Congenic Mice.- 4.4. The Major Histocompatibility (HLA System) in Humans in Relation to Aging.- 5. Immunogenetic Diseases and Aging.- 6. Summary.- References.- 13 Behavior Genetics and Aging.- 1. Introduction.- 2. Life Span.- 2.1. Inbred Mice.- 2.2. Hybrid Mice.- 2.3. Mutant Mice.- 2.4. Body-Weight Increment and Longevity.- 3. Behavior.- 3.1. Exploration and Open-Field Activity.- 3.2. Wheel Activity.- 3.3. Responsiveness to Light Onset.- 3.4. Sucrose Discrimination and Fluid Intake.- 3.5. Alcohol Preference.- 4. Summary.- References.

Read more less

Book SynopsisHow scientific advances in genetic modification will fundamentally change the natural worldThe process of manipulating the genetic material of one animal to include the DNA of another creates a new transgenic organism. Several animals, notably goats, mice, sheep, and cattle are now genetically modified in this way. In Our Transgenic Future, Lisa Jean Moore wonders what such scientific advances portend. Will the natural world become so modified that it ceases to exist? After turning species into hybrids, can we ever get back to the original, or are they forever lost? Does genetic manipulation make better lives possible, and if so, for whom?Moore centers the story on goats that have been engineered by the US military and civilian scientists using the DNA of spiders. The goat's milk contains a spider-silk protein fiber; it can be spun into ultra-strong fabric that can be used to manufacture lightweight military body armor. Researchers also hope the transgenically produced spider silk willTrade Review"Lisa Jean Moore contributes a very needed conversation regarding the ways technology is built, maintained, and destroyed, and the tensions that evolve in its creation between funding entities, scientific knowledge production, and the general public. Moore walks a narrow line between a fear of dystopian consequences and a realization of the sheer possibilities associated with their human-driven existence. Her voice is nicely interwoven with interspecies relationships, the commodification of nonhuman-nonanimal animals (at least in the natural sense), scientific facts, economic drivers, and the oft-unrealized presence of transgenic technologies in our daily lives." * Andrea Laurent-Simpson, author of Just Like Family: How Companion Animals Joined the Household *"A fascinating and fun read. Lisa Jean Moore deftly analyzes a biologically and ethically complex topic, using reflexive analyses to guide the reader along, and contributing to emergent knowledge about genetically modified animals. Moore’s reflexivity invites the reader to witness her thinking about difficult issues, and thus the book also provides a path for us as readers to think alongside her. She doesn’t tell readers what to think on the topic, or even how to think about it, but by modeling her thinking through the topic, we are able to fully grasp the issue at hand and come to our own (messy) conclusions." * Elizabeth Cherry, author of For the Birds: Protecting Wildlife through the Naturalist Gaze *"For a reader interested in the details and daily routine of this kind of scientific interaction with large animals, there is much in this book to enjoy. One may also learn something about spiders, which are undoubtedly fascinating creatures." -- John Dupré * Los Angeles Review of Books *"Moore's narration is delicate, respectful, and wonder-filled... genuinely fun and eminently accessible. Lisa Jean Moore’s Our Transgenic Future is an entertaining, thoughtful inquiry into genetic engineering in general and all of the many ethical questions that it raises." -- Rebecca Coffey * Forbes *

Read more less

Book SynopsisHistory of Clinical Cytogenetics.- DNA, Chromosomes, and Cell Division.- Human Chromosome Nomenclature: An Overview and Definition of Terms.- Basic Cytogenetics Laboratory Procedures.- The Essentials of Light Microscopy.- Quality Control & Quality Assurance.- Instrumentation in the Cytogenetics Laboratory.- Autosomal Aneuploidy.- Structural Chromosome Rearrangements.- Sex Chromosomes, Sex Chromosome Disorders, and Disorders of Sex Development.- The Cytogenetics of Infertility.- Prenatal Cytogenetics.- The Cytogenetics of Spontaneous Abortion.- Chromosome Instability.- The Cytogenetics of Hematologic Neoplasms.- The Cytogenetics of Solid Tumors.- Fluorescence in situ Hybridization (FISH).- Microarray-Based Cytogenetics.- Fragile X: A Family of Disorders: Changing Phenotype and Molecular Genetics.- Genomic Imprinting and Uniparental Disomy.- Genetic Counseling.Trade ReviewFrom the reviews of the third edition:“The audience includes those performing clinical cytogenetic testing or using results for genetic counseling or clinical care. It also would be of interest to anyone interested in cytogenetic analysis and application, from healthcare providers … to the educated lay public. … This is truly a remarkable and comprehensive book on clinical cytogenetics. … You would also want this book as a handy reference for which genetic abnormality is associated with what disease, and the best test method to use to identify the suspected abnormality.” (Valerie Ng, Doody’s Book Reviews, July, 2013)Table of ContentsSECTION 1 - Basic Concepts and Background1. History of Clinical CytogeneticsSteven L. Gersen2. DNA, Chromosomes, and Cell Division Martha B. Keagle3. Human Chromosome Nomenclature: An Overview and Definition of TermsMarilyn L. Slovak, Aaron Theisen, and Lisa G. ShafferSECTION II - Examining and Analyzing Chromosomes4. Basic Cytogenetics Laboratory ProceduresMartha B. Keagle and Steven L. Gersen5. The Essentials of Light MicroscopyNathan Claxton and Stephen Ross6. Quality Control & Quality AssuranceMartha B. Keagle7. Instrumentation in the Cytogenetics LaboratorySteven L. GersenSECTION III – Clinical Cytogenetics8. Autosomal AneuploidyJin-Chen C. Wang9. Structural Chromosome RearrangementsKathleen Kaiser-Rogers and Kathleen Rao10. Sex Chromosomes, Sex Chromosome Disorders, and Disorders of Sex DevelopmentCynthia M. Powell11. The Cytogenetics of InfertilityLinda Marie Randolph12. Prenatal CytogeneticsLinda Marie Randolph13. The Cytogenetics of Spontaneous AbortionSolveig M. V. Pflueger14. Chromosome InstabilityXiao-Xiang ZhangSECTION IV – Cancer Cytogenetics15. The Cytogenetics of Hematologic NeoplasmsAurelia Meloni-Ehrig16. The Cytogenetics of Solid Tumors Linda D. Cooley and Kathleen S. WilsonSECTION V - Adjunct Technologies17. Fluorescence in situ Hybridization (FISH)Daynna J. Wolff18. Microarray-Based CytogeneticsLisa G. ShafferSECTION VI – Beyond Chromosomes19. Fragile X: A Family of Disorders: Changing Phenotype and Molecular GeneticsElaine B. Spector 20. Genomic Imprinting and Uniparental DisomyJin-Chen C. Wang21. Genetic CounselingSarah Hutchings Clark

Read more less

Book SynopsisMolecular Genetics and Genetic Variation.- Terminology, Concepts, and Models in Genetic Epidemiology.- An Introduction to Epidemiology.- Genetic Distance and Markers Used in Linkage Mapping.- Approaches to Genetic Linkage Analysis.- Fine-Scale Structure of the Genome and Markers Used in Association Mapping.- Genome-Wide Association Studies.- Candidate Gene Association Studies.- Family-Based Association Studies.- Genome Variation: A Review of Web Resources.- Advanced Methods in Twin Studies.- Mendelian Randomization: A Tool for Assessing Causality in Observational Epidemiology.- Copy Number Variation.- Epigenetic Variation.- Modeling the Effect of Susceptibility Factors (HLA and PTPN22) in Rheumatoid Arthritis.- Coronary Artery Disease: An Example Case Study.- The Genetic Epidemiology of Obesity: A Case Study.Table of ContentsPart I: Introduction 1. Molecular Genetics and Genetic Variation Mohammed Elfatih Twfieg and M. Dawn Teare 2. Terminology, Concepts, and Models in Genetic Epidemiology M. Dawn Teare and Mauro F Santibàñez Koref 3. An Introduction to Epidemiology Cother Hajat Part II: Genetic Linkage Mapping 4. Genetic Distance and Markers Used in Linkage Mapping Kristina Allen-Brady and Nicola J. Camp 5. Approaches to Genetic Linkage Analysis M. Dawn Teare Part III: Genetic Mapping by Association 6. Fine-Scale Structure of the Genome and Markers Used in Association Mapping Karen Curtin and Nicola J. Camp 7. Genome-Wide Association Studies Mark M. Iles 8. Candidate Gene Association Studies M. Dawn Teare 9. Family-Based Association Studies Frank Dudbridge 10. Genome Variation: A Review of Web Resources Andrew Collins and William Tapper Part IV: Emerging Themes 11. Advanced Methods in Twin Studies Jaakko Kaprio and Karri Silventoinen 12. Mendelian Randomization: A Tool for Assessing Causality in Observational Epidemiology Nuala A. Sheehan, Sha Meng, and Vanessa Didelez 13. Copy Number Variation Louise V. Wain and Martin D. Tobin 14. Epigenetic Variation Kevin Walters Part V: Case Studies 15. Modeling the Effect of Susceptibility Factors (HLA and PTPN22) in Rheumatoid Arthritis Hervé Perdry and Françoise Clerget-Darpoux 16. Coronary Artery Disease: An Example Case Study Jennifer H. Barrett 17. The Genetic Epidemiology of Obesity: A Case Study Laura Johnson

Read more less

Book SynopsisGenetic epidemiology plays a key role in discovering genetic factors influencing health and disease, and in understanding how genes and environmental risk factors interact. There is growing interest in this field within public health, with the goal of translating the results into promoting health and preventing disease in both families and populations. This textbook provides graduate students with a working knowledge of genetic epidemiology research methods. Following an overview of the field, the book reviews key genetic concepts, provides an update on relevant genomic technology, including genome-wide chips and DNA sequencing, and describes methods for assessing the magnitude of genetic influences on diseases and risk factors. The book focuses on research study designs for discovering disease susceptibility genes, including family-based linkage analysis, candidate gene and genome-side association studies, assessing gene-environment interactions and epistasis, studies of Non-Mendelian inheritance, and statistical analyses of data from these studies. Specific applications of each research method are illustrated using a variety of diseases and risk factors relevant to public health, and useful web-based genetic analysis software, human reference panels, and repositories, that can greatly facilitate this work, are described. Concluding with a review of ethical issues and a framework for translating human genomics research to clinical practice and public health benefit, this textbook is an essential new resource for graduate students in epidemiology and public health genetics.Table of Contentsa: Foreword 1: The Evolving Field of Genetic Epidemiology 2: Assessing Genetic Influences on Diseases and Risk Factors 3: Genetic Concepts and Genomic Technology for Genetic Epidemiology 4: Family Studies in Genetic Epidemiology: From Linkage to Exome Sequencing 5: Genetic Association Studies 6: Population Stratification in Genetic Association Studies 7: Gene–Environment Interactions and Epistasis 8: Non-Mendelian Genetics 9: Software and Data Resources for Genetic Epidemiology Studies 10: Ethical Issues in Genetic Epidemiology 11: Public Health and Clinical Applications of Genetic Epidemiology

Read more less